<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pembrolizumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pembrolizumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pembrolizumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="96958" href="/d/html/96958.html" rel="external">see "Pembrolizumab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="113354" href="/d/html/113354.html" rel="external">see "Pembrolizumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F25871640"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Keytruda</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871806"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Keytruda</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25808624"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-PD-1 Monoclonal Antibody;</li>
<li>
                        Antineoplastic Agent, Immune Checkpoint Inhibitor;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F25857279"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Some indications are based on PD-L1 expression, or are based on tumor specimen microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), mismatch repair proficient (pMMR), or tumor mutational burden-high (TMB-H) status.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b49fc8cc-4532-40a9-993c-98caca837585">Biliary tract cancer, locally advanced unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, locally advanced unresectable or metastatic: IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, in combination with cisplatin (maximum 8 cycles) and gemcitabine; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37075781','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37075781','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d4e2e8c-575d-4763-beee-55b41ad8deb9">Breast cancer, triple-negative, high-risk, early stage, neoadjuvant and adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, triple-negative, high-risk, early stage, neoadjuvant and adjuvant therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neoadjuvant therapy (pembrolizumab in combination with chemotherapy for 24 weeks): </i>
<b>IV: </b>200 mg once every 3 weeks for 8 doses <b>or </b>400 mg once every 6 weeks for 4 doses, or until disease progression or unacceptable toxicity (do not administer adjuvant therapy if disease progression or unacceptable toxicity occurs with neoadjuvant therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy (pembrolizumab as a single agent for up to 27 weeks):</i>
<b>IV: </b>200 mg once every 3 weeks for 9 doses <b>or</b> 400 mg once every 6 weeks for 5 doses, or until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Trial-specific dosing details: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neoadjuvant therapy: </i>
<b>IV: </b>200 mg once every 3 weeks (in combination with paclitaxel and carboplatin) for 4 cycles (first neoadjuvant treatment), followed by 200 mg once every 3 weeks (in combination with cyclophosphamide and either doxorubicin or epirubicin) for 4 cycles (second neoadjuvant treatment). Patients underwent definitive surgery 3 to 6 weeks after the last cycle of the neoadjuvant phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35139274','lexi-content-ref-32101663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35139274','lexi-content-ref-32101663'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adjuvant therapy:</i>
<b>IV: </b>200 mg once every 3 weeks (in combination with radiation therapy) for up to 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35139274','lexi-content-ref-32101663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35139274','lexi-content-ref-32101663'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fce5e9c1-723d-47b1-bf67-51b3f16a65ea">Breast cancer, triple-negative, locally recurrent unresectable or metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, triple-negative, locally recurrent unresectable or metastatic, with PD-L1 expression (combined positive score ≥10): IV: </b>200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months. Administer in combination with chemotherapy; in the clinical trial, chemotherapy consisted of paclitaxel (protein bound), paclitaxel (conventional), or gemcitabine/carboplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33278935','lexi-content-ref-35857659','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33278935','lexi-content-ref-35857659','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="948aad46-2211-4e51-8eff-038c3579131c">Cervical cancer, stage III to IVA</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Cervical cancer, stage III to IVA: IV: </b>200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; in combination with 5 to 6 cycles of cisplatin-based chemoradiotherapy, followed by brachytherapy; continue pembrolizumab (as a single agent) until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5ff9b92-83c7-40cd-9bd1-29c4c89b0444">Cervical cancer, persistent, recurrent, or metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, persistent, recurrent, or metastatic, with PD-L1 expression (CPS ≥1):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30943124','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30943124','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg once every 3 weeks <b> or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months. Administer in combination with chemotherapy, with or without bevacizumab; in the clinical trial, chemotherapy consisted of paclitaxel in combination with either cisplatin or carboplatin (with or without bevacizumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34534429','lexi-content-ref-37910822','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34534429','lexi-content-ref-37910822','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9dd0e259-532a-4935-bc75-3cba92c3f393">Colorectal cancer, unresectable or metastatic, microsatellite instability-high or mismatch repair deficient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, unresectable or metastatic, microsatellite instability-high or mismatch repair deficient: IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33264544','lexi-content-ref-35427471','lexi-content-ref-31725351','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33264544','lexi-content-ref-35427471','lexi-content-ref-31725351','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="163d9b86-f77d-43de-b90d-e6eb9a9bfe95">Cutaneous squamous cell carcinoma, recurrent, metastatic, or locally advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous squamous cell carcinoma, recurrent, metastatic, or locally advanced:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32673170','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32673170','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6d001b2-4849-4994-a91e-d5920f3dc04e">Endometrial carcinoma, advanced, mismatch repair proficient or not microsatellite instability-high</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, advanced, mismatch repair proficient or not microsatellite instability-high: IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, in combination with lenvatinib; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35045221','lexi-content-ref-37058687','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35045221','lexi-content-ref-37058687','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5daa6e38-27aa-4ebe-95ff-45f2a6aac7eb">Endometrial carcinoma, advanced microsatellite instability-high or mismatch repair deficient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, advanced, microsatellite instability-high or mismatch repair deficient: IV: </b>200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34990208','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34990208','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fc83be5-67d0-4503-8e4d-666969a9ab75">Esophageal cancer, recurrent locally advanced or metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, recurrent locally advanced or metastatic, with PD-L1 expression (CPS ≥10): IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33026938','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33026938','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0f8493c-868b-45e3-ade2-2906fcc06332">Esophageal cancer, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, locally advanced or metastatic:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, in combination with 6 cycles of fluorouracil and cisplatin; continue pembrolizumab and fluorouracil until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34454674','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34454674','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8ab7b91-2833-4731-b1ef-b5330a87af33">Gastric cancer, locally advanced or metastatic, HER2-positive, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, locally advanced or metastatic, HER2-positive, with PD-L1 expression (CPS ≥1) (first-line therapy): IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34912120','lexi-content-ref-37871604','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34912120','lexi-content-ref-37871604','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f276a5b5-1b4d-4dc7-b1c1-c975e8462abf">Gastric cancer, locally advanced or metastatic, HER2-negative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, locally advanced or metastatic, HER2-negative (first-line therapy): IV: </b>200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks, in combination with fluoropyrimidine- and platinum-containing chemotherapy; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37875143','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37875143','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b1ccad8-e29e-47c5-aa61-c1d829a1605e">Head and neck cancer, squamous cell carcinoma, unresectable, recurrent, or metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer, squamous cell carcinoma, unresectable, recurrent, or metastatic, with PD-L1 expression (CPS ≥1) (first-line therapy): IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955135','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955135','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc710244-3386-465b-b24c-27bab6b4b09f">Head and neck cancer, squamous cell carcinoma, unresectable, recurrent, or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer, squamous cell carcinoma, unresectable, recurrent, or metastatic (first-line therapy): IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks, in combination with 6 cycles of fluorouracil and either carboplatin or cisplatin; continue pembrolizumab (as a single agent) until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31679945','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31679945','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d807adbd-d5e1-4670-a241-7a1012c77d9e">Hepatocellular carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, advanced:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29875066','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29875066','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd49695e-08bd-486a-972b-1397b8d01684">Hodgkin lymphoma, classical, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, classical, relapsed or refractory:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28441111','lexi-content-ref-31409671','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28441111','lexi-content-ref-31409671','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99d76069-64b1-4537-b346-60d806aff488">Malignant pleural mesothelioma, relapsed or refractory, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma, relapsed or refractory, with PD-L1 expression (off-label use): IV:</b> 200 mg once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291584','lexi-content-ref-30142389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291584','lexi-content-ref-30142389'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4424fb62-fa4f-4156-9385-44a6005d1d94">Melanoma, stage IIB, IIC, or III, resected, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, stage IIB, IIC, or III, resected, adjuvant therapy: IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks; continue until disease recurrence, unacceptable toxicity, or (in patients without disease recurrence) for up to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658430','lexi-content-ref-35367007','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658430','lexi-content-ref-35367007','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b074c6da-efdb-4e92-8cb1-28d793d556df">Melanoma, advanced, high-risk, resectable, neoadjuvant and adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, advanced, high-risk, resectable, neoadjuvant and adjuvant therapy (off-label use): IV:</b> 200 mg once every 3 weeks for a total of 3 neoadjuvant doses prior to surgery (the interval between the last neoadjuvant dose and surgery should be no longer than 5 weeks), followed by 200 mg once every 3 weeks for an additional 15 doses as postsurgery adjuvant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36856617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36856617'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b8b61a8-a96f-4706-a076-2ede2ffc94b3">Melanoma, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cfdb7fc6-c284-47b1-aed0-5892a43d7a41">Merkel cell carcinoma, recurrent locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, recurrent locally advanced or metastatic: IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9ec23f8-6dd0-40ae-8654-caeb8fdb8a22">Microsatellite instability-high or mismatch repair-deficient cancer, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Microsatellite instability-high or mismatch repair-deficient cancer, unresectable or metastatic: IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31682550','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31682550','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84796290-5081-46b8-9782-5f4b6a485404">Mycosis fungoides/Sézary syndrome, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycosis fungoides/Sézary syndrome, relapsed or refractory (off-label use):</b>
<b>IV:</b> 2 mg/kg once every 3 weeks until disease progression or unacceptable toxicity, for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532724'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49fd4f19-c4fb-48ec-9c9d-dc6db2c2bc5d">Non–small cell lung cancer, stage IB, II, or IIIA, resected, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, stage IB, II, or IIIA, resected, adjuvant therapy: IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks; continue until disease recurrence, unacceptable toxicity, or for up to 12 months in patients without disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36108662','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36108662','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ac22a36-7dc4-45a3-a1b1-2d835bfbd84f">Non–small cell lung cancer, resectable, neoadjuvant and adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–</b>
<b>small cell lung cancer, resectable, neoadjuvant and adjuvant therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neoadjuvant therapy (in combination with chemotherapy for 12 weeks): </i>
<b>IV: </b>200 mg once every 3 weeks for 4 doses <b>or </b>400 mg once every 6 weeks for 2 doses, or until disease progression that precludes definitive surgery or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy (as a single agent for up to 39 weeks):</i>
<b>IV: </b>200 mg once every 3 weeks for 13 doses <b>or</b> 400 mg once every 6 weeks for 7 doses, or until disease recurrence or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Trial-specific dosing details: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neoadjuvant therapy: </i>
<b>IV: </b>200 mg once every 3 weeks (in combination with cisplatin and gemcitabine [squamous histology] <b>or</b> cisplatin and pemetrexed [nonsquamous histology]) for 4 cycles. Patients underwent definitive surgery within 20 weeks after the first cycle of the neoadjuvant phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37272513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37272513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adjuvant therapy:</i>
<b>IV: </b>200 mg once every 3 weeks (as a single agent) for up to 13 cycles. Patients initiated adjuvant therapy no sooner than 4 weeks and no later than 12 weeks following definitive surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37272513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37272513'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="029bed87-f428-4069-b622-40299e1fd0ce">Non–small cell lung cancer, stage III or metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, stage III or metastatic, with PD-L1 expression (</b>
<b>tumor proportion score ≥1%) (first-line therapy)</b>
<b>:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30955977','lexi-content-ref-27718847','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30955977','lexi-content-ref-27718847','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bd3a9ec-948c-4da4-a29f-527a53d0b702">Non–small cell lung cancer, metastatic, with PD-L1 expression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, with PD-L1 expression (tumor proportion score </b>
<b>≥1%) (previously treated): IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64968485-ece1-4404-8123-8854da9806e9">Non–small cell lung cancer, metastatic, nonsquamous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, nonsquamous (first-line therapy):</b> IV: 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, in combination with pemetrexed and either cisplatin or carboplatin for 4 cycles, followed by pembrolizumab monotherapy of 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, with or without optional indefinite pemetrexed maintenance therapy; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for a total duration of pembrolizumab therapy of up to 35 cycles or 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658856','lexi-content-ref-27745820','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658856','lexi-content-ref-27745820','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96bcad70-4fbe-497a-a5d0-7069ccdb9cc9">Non–small cell lung cancer, metastatic, squamous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, squamous (first-line therapy):</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, in combination with carboplatin and either paclitaxel or paclitaxel (protein bound) for 4 cycles, followed by pembrolizumab monotherapy of 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks until radiographic disease progression, unacceptable toxicity, or (in patients without disease progression) for a total duration of pembrolizumab therapy of up to 35 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280635','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280635','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ee8c1f2-327c-4abc-a7e9-155e29b117db">Primary mediastinal large B-cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary mediastinal large B-cell lymphoma, relapsed or refractory: IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31609651','lexi-content-ref-37130017','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31609651','lexi-content-ref-37130017','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aae804-1237-4204-9c28-e9e2244abf05">Renal cell carcinoma, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, adjuvant therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use (as a single-agent) in patients at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks; continue until disease recurrence, unacceptable toxicity, or (in patients without disease recurrence) for up to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34407342','lexi-content-ref-36055304','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34407342','lexi-content-ref-36055304','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="045bd6ae-3edd-419a-aa75-2a643fc49694">Renal cell carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced (first-line therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy (off-label use): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used as monotherapy in patients with limited burden, favorable-risk disease when ipilimumab-based regimens or antiangiogenic agents are not appropriate options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35728020','lexi-content-ref-George.1','lexi-content-ref-33529051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35728020','lexi-content-ref-George.1','lexi-content-ref-33529051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33529051','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33529051','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in combination with either axitinib or lenvatinib regardless of risk stratification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33616314','lexi-content-ref-30779529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33616314','lexi-content-ref-30779529'])">Ref</a></span>); some experts may prefer pembrolizumab in combination with axitinib for patients with favorable-risk disease who have substantial disease burden, and pembrolizumab in combination with lenvatinib for patients with intermediate- or poor-risk disease who have symptomatic or life-threatening disease burden (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg once every 3 weeks <b>or</b> 400 mg once every 6 weeks, in combination with axitinib or lenvatinib; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33616314','lexi-content-ref-33284113','lexi-content-ref-30779529','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33616314','lexi-content-ref-33284113','lexi-content-ref-30779529','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af7c106a-6cb0-48c4-8a2c-468b1b3306c1">Tumor mutational burden-high cancer, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tumor mutational burden-high cancer, unresectable or metastatic: IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32919526','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32919526','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48c1fa50-d14a-4e16-a385-3fd4b8874621">Urothelial cancer, non-muscle invasive, high-risk, Bacillus Calmette-Guerin–unresponsive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, non-muscle invasive, high-risk, Bacillus Calmette-Guerin–unresponsive:</b>
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks until persistent or recurrent non-muscle invasive bladder cancer, disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34051177','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34051177','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1561b68-4de4-4f0a-9e05-23c88c54b83a">Urothelial cancer, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, locally advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28212060','lexi-content-ref-32552471','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28212060','lexi-content-ref-32552471','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 mg once every 3 weeks <b>or </b>400 mg once every 6 weeks, in combination with enfortumab vedotin; continue until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36041086','lexi-content-ref-37369081','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36041086','lexi-content-ref-37369081','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990672"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment </i>
<b>
<i>prior </i></b>
<i>to treatment initiation: </i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b>
<i></i>No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (large molecular weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30298302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30298302'])">Ref</a></span>): No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>). Several cases of successful use in patients with end-stage kidney disease have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27659911','lexi-content-ref-29764752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27659911','lexi-content-ref-29764752'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large molecular weight): No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, slow, low efficiency hemodiafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney toxicity <b>during </b>treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated nephritis with kidney dysfunction:</i>
<b>Note:</b> If pembrolizumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or grade 3 serum creatinine elevation: Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 serum creatinine elevation: Permanently discontinue pembrolizumab.</p></div>
<div class="block doha drugH1Div" id="F50987936"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment <i>prior</i> to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling; however, there was no clinically important effect on clearance for patients with mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) to severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity <i>during</i> treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If pembrolizumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Indications </i>
<b>
<i>except</i></b>
<i> when used in combination with axitinib (for renal cell carcinoma):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Immune-mediated hepatitis <b>without</b> tumor involvement of the liver:</p>
<p style="text-indent:-2em;margin-left:10em;">AST or ALT &gt;3 up to 8 times ULN or total bilirubin &gt;1.5 up to 3 times ULN: Withhold pembrolizumab treatment. Resume pembrolizumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:10em;">AST or ALT &gt;8 times ULN or total bilirubin &gt;3 times ULN: Discontinue pembrolizumab permanently.</p>
<p style="text-indent:-2em;margin-left:8em;">Immune-mediated hepatitis <b>with </b>tumor involvement of the liver: <b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:10em;">If baseline AST or ALT &gt;1 up to 3 times ULN and increases to &gt;5 up to 10 times ULN or baseline AST or ALT &gt;3 up to 5 times ULN and increases to &gt;8 up to 10 times ULN: Withhold pembrolizumab treatment. Resume pembrolizumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:10em;">AST or ALT increases to &gt;10 times ULN or total bilirubin increases to &gt;3 times ULN: Discontinue pembrolizumab permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>When used in combination with <b>axitinib</b> (for renal cell carcinoma):</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT ≥3 to &lt;10 times ULN without concurrent total bilirubin ≥2 times ULN: Withhold pembrolizumab (and axitinib) treatment until recovery to grade 0 or 1. After recovery, consider rechallenge with a single drug (either pembrolizumab or axitinib) or sequential rechallenge with both pembrolizumab and axitinib; axitinib may require a dose reduction (refer to axitinib monograph).</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT ≥10 times ULN <b>or</b> &gt;3 times ULN with concurrent total bilirubin ≥2 times ULN: Discontinue pembrolizumab (and axitinib) permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Addition</b>
<b>al recommendations for hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2 immune-mediated hepatitis:</i> Withhold immune checkpoint inhibitor (ICI); if no improvement within 3 to 5 days after ICI is withheld, consider initiation of corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) (ASCO [Schneider 2021]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4 immune-mediated hepatitis:</i> Withhold ICI; initiate corticosteroids (methylprednisolone 1 to 2 mg/kg or equivalent) (ASCO [Schneider 2021]). Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with methylprednisolone 1 mg/kg/day demonstrated similar time to ALT normalization (compared with higher methylprednisolone doses), while reducing the potential for corticosteroid-related complications (Li 2022).</p></div>
<div class="block doo drugH1Div" id="F57498349"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2 </sup>experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F25860612"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> No dosage reductions of pembrolizumab are recommended. Other concomitant anticancer therapies may also require treatment interruption, dosage reduction, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Immune-mediated adverse reactions (general information):</i></b> Withhold pembrolizumab for severe (grade 3) immune-mediated adverse reactions. Permanently discontinue pembrolizumab for life-threatening (grade 4) immune-mediated adverse reactions, recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or inability to reduce corticosteroid dose to prednisone ≤10 mg/day (or equivalent) within 12 weeks of initiating corticosteroids. If pembrolizumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) until improvement to ≤ grade 1; upon improvement to ≤ grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with corticosteroid therapy. Systemic corticosteroids may not be necessary for certain adverse reactions. Hormone replacement therapy may be required for endocrinopathies (if clinically indicated). See table for additional dosage modification guidance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Additional management </i>
<i>recommendations:</i></b>Consider withholding checkpoint inhibitor therapy for most grade 2 toxicities and resume when symptoms and/or lab values resolve to ≤ grade 1; systemic corticosteroids (initial dose of 0.5 to 1 mg/kg/day prednisone [or equivalent]) may be administered if indicated for grade 2 toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Refer to guideline for further information regarding management of immune-mediated adverse reactions associated with checkpoint inhibitor therapy.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Pembrolizumab dosage modification</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Refer to prednisone monograph for tapering recommendations when used for immune-mediated adverse reactions associated with checkpoint inhibitor therapy.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">Immune-mediated adverse reactions</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Cardiovascular toxicity: Myocarditis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2, 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Dermatologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Mild or moderate nonexfoliative rash</p></td>
<td align="center">
<p style="text-indent:0em;">May be managed with topical emollients and/or topical corticosteroids.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Exfoliative dermatologic conditions: Suspected Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS)</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper.<sup>a</sup> Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Confirmed SJS, TEN, or DRESS</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="center" rowspan="6">
<p style="text-indent:0em;">Endocrinopathies</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab until clinically stable or permanently discontinue depending on severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Adrenal insufficiency, ≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate symptomatic management (including hormone replacement as clinically indicated).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Diabetes, type 1</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate insulin as clinically indicated. Long-term insulin therapy may be required.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypophysitis</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold or discontinue pembrolizumab (depending on the severity). Initiate hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hyperthyroidism/Thyroiditis</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold or discontinue pembrolizumab (depending on the severity). Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypothyroidism</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab (depending on the severity). Initiate thyroid hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">GI toxicity: Colitis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2 or 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper.<sup>a</sup> Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hematologic toxicity (in patients with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma)</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab until resolution to grade 0 or 1.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Neurologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper.<sup>a</sup> Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Ocular disorders: Vogt-Koyanagi-Harada-like syndrome</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">May require systemic corticosteroids to reduce the risk of permanent vision loss.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Pulmonary toxicity: Pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper.<sup>a</sup> Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">Other adverse reactions</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Infusion reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt or slow the rate of pembrolizumab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Stop infusion and permanently discontinue pembrolizumab.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F25860609"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F49729571"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="113354" href="/d/html/113354.html" rel="external">see "Pembrolizumab: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> FDA approval for some indications through an accelerated process.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="777ae95c-2192-4339-afe2-a5cf337c04d1">Hodgkin lymphoma, classical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, classical (relapsed or refractory):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IV: 2 mg/kg/dose; maximum dose: 200 mg/dose; administer once every 3 weeks until disease progression, unacceptable toxicity, or in patients without disease progression, for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48233bc4-e581-4f2e-abf7-be45d2f3898e">Melanoma; stage IIB, IIC, or III following complete resection, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma; stage IIB, IIC, or III following complete resection, adjuvant therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: 2 mg/kg/dose; maximum dose: 200 mg/dose; administer once every 3 weeks until disease progression, unacceptable toxicity, or in patients without disease progression, for up to 12 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1c0ac3-f816-496c-b795-1ed8749c88b2">Merkel cell carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma (recurrent locally advanced or metastatic):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IV: 2 mg/kg/dose; maximum dose: 200 mg/dose; administer once every 3 weeks until disease progression, unacceptable toxicity, or in patients without disease progression, for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f20fabd7-e448-4c33-aff3-95c5cb8226b3">Microsatellite instability-high cancer; non-CNS solid tumors that have progressed following prior treatment without satisfactory alternative treatment options</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Microsatellite instability-high cancer (MSI-H) (unresectable or metastatic); non-CNS solid tumors that have progressed following prior treatment without satisfactory alternative treatment options: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IV: 2 mg/kg/dose; maximum dose: 200 mg/dose; administer once every 3 weeks until disease progression, unacceptable toxicity, or in patients without disease progression, for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="110292f2-f0f7-4f0b-88d5-496c57489915">Primary mediastinal large B-cell lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary mediastinal large B-cell lymphoma (PMBCL) (relapsed or refractory):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IV: 2 mg/kg/dose; maximum dose: 200 mg/dose; administer once every 3 weeks until disease progression, unacceptable toxicity, or in patients without disease progression, for up to 24 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="543e18b3-2c61-4705-8da0-05c3b2ce2f79">Tumor mutational burden-high; non-CNS solid tumors that have progressed following prior treatment without satisfactory alternative treatment options</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tumor mutational burden-high (TMB-H) (unresectable or metastatic); non-CNS solid tumors that have progressed following prior treatment without satisfactory alternative treatment options:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IV: 2 mg/kg/dose; maximum dose: 200 mg/dose; administer once every 3 weeks until disease progression, unacceptable toxicity, or in patients without disease progression, for up to 24 months. <b>Note:</b> TMB-H defined as ≥10 mutations/megabase (Mut/Mb) and determined by an FDA-approved test.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">In general, no dosage reductions of pembrolizumab are recommended; pembrolizumab therapy is withheld or discontinued to manage toxicities. Concomitant medications may also require treatment interruption, dosage reduction, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Immune-mediated adverse reactions (general information):</b></i> Withhold pembrolizumab for severe (grade 3) immune-mediated adverse reactions. Permanently discontinue pembrolizumab for life-threatening (grade 4) immune-mediated adverse reactions, recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or inability to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of initiating corticosteroids. If pembrolizumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) until improvement to ≤ grade 1; upon improvement to ≤ grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with corticosteroid therapy. Systemic corticosteroids may not be necessary for certain adverse reactions. Hormone replacement therapy may be required for endocrinopathies (if clinically indicated). See table for additional dosage modification guidance.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Pembrolizumab Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="left">
<p style="text-indent:0em;">Severity</p></th>
<th align="left">
<p style="text-indent:0em;">Pembrolizumab dosage modification</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<i>Immune-mediated adverse reactions</i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Cardiovascular toxicity: Myocarditis</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2, 3, or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;">Dermatologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;">Mild or moderate nonexfoliative rash</p></td>
<td align="left">
<p style="text-indent:0em;">May be managed with topical emollients and/or topical corticosteroids.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Exfoliative dermatologic conditions: Suspected Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS)</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Confirmed SJS, TEN, or DRESS</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="left" rowspan="6">
<p style="text-indent:0em;">Endocrinopathies</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab until clinically stable or permanently discontinue depending on severity.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Adrenal insufficiency, ≥ grade 2</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab depending on the severity. Initiate symptomatic management (including hormone replacement as clinically indicated).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Diabetes, type 1</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab depending on the severity. Initiate insulin as clinically indicated. Long-term insulin therapy may be required.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypophysitis</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold or discontinue pembrolizumab (depending on the severity). Initiate hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hyperthyroidism</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold or discontinue pembrolizumab (depending on the severity). Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypothyroidism</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold or discontinue pembrolizumab (depending on the severity). Initiate thyroid hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">GI toxicity: Colitis</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2 or 3</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hematologic toxicity (in patients with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma)</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab until resolution to grade 0 or 1.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Neurologic toxicities</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Ocular disorders: Vogt-Koyanagi-Harada-like syndrome</p></td>
<td align="left"></td>
<td align="left">
<p style="text-indent:0em;">May require systemic corticosteroids to reduce the risk of permanent vision loss.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Pulmonary toxicity: Pneumonitis</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue pembrolizumab.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<i>Other adverse reactions</i></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Infusion reactions</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt or slow the rate of pembrolizumab infusion.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Stop infusion and permanently discontinue pembrolizumab.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F51152521"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline renal impairment:</i> There are no dosage adjustments provided in the manufacturer's labeling. In a pharmacokinetic study including adolescents ≥15 years of age, no difference in clearance was noted for patients with eGFR ≥15 mL/minute/1.73 m<sup>2</sup>; no dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nephrotoxicity <b>during</b> therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immune-mediated nephritis with kidney dysfunction: If pembrolizumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">Grade 2 or grade 3 serum creatinine elevation: Withhold pembrolizumab; resume pembrolizumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:8em;">Grade 4 serum creatinine elevation: Permanently discontinue pembrolizumab.</p></div>
<div class="block dohp drugH1Div" id="F51152522"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling; however, there was no clinically important effect on clearance for patients with mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) to severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity <b>during </b>treatment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">If pembrolizumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper. Permanently discontinue pembrolizumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce corticosteroid dose to the equivalent of prednisone ≤10 mg/day in adults within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:8em;">Immune-mediated hepatitis <b>without</b> tumor involvement of the liver:</p>
<p style="text-indent:-2em;margin-left:10em;">AST or ALT &gt;3 up to 8 times ULN or total bilirubin &gt;1.5 up to 3 times ULN: Withhold pembrolizumab treatment. Resume pembrolizumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:10em;">AST or ALT &gt;8 times ULN or total bilirubin &gt;3 times ULN: Discontinue pembrolizumab permanently.</p>
<p style="text-indent:-2em;margin-left:8em;">Immune-mediated hepatitis <b>with </b>tumor involvement of the liver: <b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:10em;">Baseline AST or ALT increases &gt;1 up to 3 times ULN and increases to &gt;5 up to 10 times ULN or baseline AST or ALT &gt;3 up to 5 times ULN and increases to &gt;8 up to 10 times ULN: Withhold pembrolizumab treatment. Resume pembrolizumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:10em;">AST or ALT increases to &gt;10 times ULN or total bilirubin increases to &gt;3 times ULN: Discontinue pembrolizumab permanently.</p></div>
<div class="block arsc drugH1Div" id="F55615147"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myocardial infarction</b> and immune mediated<b> myocarditis, pericarditis, and vasculitis </b>have occurred with pembrolizumab. Cardiovascular events are potentially fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189042','lexi-content-ref-29536852','lexi-content-ref-36875060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189042','lexi-content-ref-29536852','lexi-content-ref-36875060'])">Ref</a></span>). Myocarditis may overlap with <b>myositis</b> and <b>myasthenia gravis</b> in patients receiving immune checkpoint inhibitors. Death occurred in 46% of patients with severe myocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536852'])">Ref</a></span>). Vasculitis has been reported in large, medium, and small vessels as well as the CNS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism is unknown. Evolving data suggest the presence of common high frequency T‐cell receptors in cardiac muscle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29802219','lexi-content-ref-27806233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29802219','lexi-content-ref-27806233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median reported onset of myocarditis is ~30 to 65 days, with most cases occurring in the first 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29158217','lexi-content-ref-29802219','lexi-content-ref-29567210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29158217','lexi-content-ref-29802219','lexi-content-ref-29567210'])">Ref</a></span>). Late presentations of up to 454 days have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29158217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29158217'])">Ref</a></span>). Median onset of vasculitis is 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27806233','lexi-content-ref-28241095','lexi-content-ref-29320654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27806233','lexi-content-ref-28241095','lexi-content-ref-29320654'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29567210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29567210'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29567210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29567210'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated rashes, including <b>Stevens-Johnson syndrome</b> (SJS),<b> toxic epidermal necrolysis </b>([TEN] some fatal), exfoliative dermatitis, and <b>bullous pemphigoid</b> may occur with pembrolizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31810421','lexi-content-ref-31511479','lexi-content-ref-29885481','lexi-content-ref-30086678','lexi-content-ref-28228726','lexi-content-ref-26371282','lexi-content-ref-28438440','lexi-content-ref-31008169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31810421','lexi-content-ref-31511479','lexi-content-ref-29885481','lexi-content-ref-30086678','lexi-content-ref-28228726','lexi-content-ref-26371282','lexi-content-ref-28438440','lexi-content-ref-31008169'])">Ref</a></span>). Among the diverse immune-related adverse events (irAEs), cutaneous toxicities such as <b>skin <b>rash</b></b>, <b>pruritus</b>, and <b>vitiligo</b> are by far the most common and the earliest to occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26629425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26629425'])">Ref</a></span>); however, rarer rashes such as <b>lichenoid eruption </b>(eg, <b>lichenoid dermatitis</b>, <b>lichen planus</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37266094','lexi-content-ref-36622668','lexi-content-ref-37332364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37266094','lexi-content-ref-36622668','lexi-content-ref-37332364'])">Ref</a></span>), <b>psoriasis flare</b> (eg, plaque) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36728879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36728879'])">Ref</a></span>), and bullous disorders including bullous pemphigoid, SJS, and TEN are of special interest due to their severity and potentially life-threatening consequences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Additional reported mucosal toxicities include <b>stomatitis</b>, gingivitis, and <b>Sjögren disease</b>-like symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787','lexi-content-ref-30005106','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787','lexi-content-ref-30005106','lexi-content-ref-34172516'])">Ref</a></span>). Although most cutaneous toxicities are transient, they can cause significant morbidity and impairment of patients’ health-related quality of life; some adverse reactions (eg, Sjögren disease) may not fully resolve, necessitating long-term treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516','lexi-content-ref-26629425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516','lexi-content-ref-26629425'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism unknown. May involve blockade of a common antigen (co-expressed on tumor cells and the dermo-epidermal junction and/or other levels of the skin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; dermatologic toxicity occurs within the first 3 to 4 weeks of therapy and may occur in patients with any tumor type (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787','lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787','lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>) but has also been reported later in therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30086678','lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30086678','lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>). Median time to onset for Sjögren disease-like symptoms is 70 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). For most patients, dermatologic toxicity is the earliest irAE experienced (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Endocrine toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Endocrine toxicities include primary <b>hypothyroidism</b>, <b>hyperthyroidism</b>, <b>adrenocortical insufficiency </b>(primary and secondary), <b>hypophysitis</b> (inflammation of the pituitary gland), and <b>type 1</b>
<b>diabetes mellitus</b> (including <b>diabetic ketoacidosis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-34172516','lexi-content-ref-22614989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-34172516','lexi-content-ref-22614989'])">Ref</a></span>). In rare cases, patients may present with adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Hypothyroidism and hyperthyroidism are frequently asymptomatic (or present with vague symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Immune-mediated endocrinopathies usually require permanent hormone replacement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787','lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; mechanisms not fully understood. Thyroid dysfunction may be due to the development of antithyroglobulin or antithyroid peroxidase antibodies. In rare cases, Graves' disease may arise due to the development of anti-thyroid-stimulating hormone receptor antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Hypophysitis may be due to humoral immunity against the pituitary gland, with involvement of the complement system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; often delayed and can appear at any time throughout treatment with checkpoint inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-22614989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28881921','lexi-content-ref-26027431','lexi-content-ref-22614989'])">Ref</a></span>). Adrenal insufficiency: Median onset of 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Hypophysitis: Median onset of 76 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Hypothyroidism: Median onset of 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Thyrotoxicosis: Median onset of 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>). Type 1 diabetes mellitus: Up to a year after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>colitis</b> has occurred, including cases of grade 2 to 4 colitis.<b> Diarrhea</b> and colitis represent a clinical spectrum where diarrhea is defined as increased stool frequency and colitis involves symptoms of <b>abdominal pain</b> and either clinical or radiologic evidence of colonic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282'])">Ref</a></span>). Colitis affecting the descending colon is one of the most common complications leading to hospitalization and increased morbidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18545145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18545145'])">Ref</a></span>). Enteritis with small bowel obstruction has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>). Complications, such as small bowel perforation, ischemia, necrosis, bleeding, and toxic megacolon may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31018834','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31018834','lexi-content-ref-34172516'])">Ref</a></span>). Colitis-related mortality is associated with delayed reporting, noncompliance with an antidiarrheal regimen, and delays in drug withholding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-26371282'])">Ref</a></span>). In a retrospective study, when re-challenged up to 34% of patients experienced a recurrence of colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-26371282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. Median onset of 5 to 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Autoimmune disorders of the GI tract (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combination therapy with anti-PD-(L)1 inhibitors and anti-CTLA-4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Gut microbiome (bacteria of the phylum Firmicutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior treatment with nonsteroidal anti-inflammatory drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hematologic immune-related adverse events occur less frequently. Severity varies from mild, asymptomatic cytopenias to more significant reports of <b> immune</b>
<b>thrombocytopenia</b>, autoimmune<b> hemolytic anemia </b>(AIHA), acquired hemophilia, and <b>disseminated intravascular coagulation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3960626','lexi-content-ref-30528137','lexi-content-ref-27367787','lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3960626','lexi-content-ref-30528137','lexi-content-ref-27367787','lexi-content-ref-30347480'])">Ref</a></span>). Development of higher grades of <b>anemia </b>have led to treatment discontinuation in a small percentage of patients treated for head and neck cancers, urothelial and cervical cancer, and non-small cell lung cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367787']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367787'])">Ref</a></span>). Although the incidence for AIHA is rare, it can result in fatalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). AIHA was significantly more common with anti-PD-1/PD-L1 monoclonal antibodies (ie, nivolumab, pembrolizumab, atezolizumab) than with anti-CTLA-4 monoclonal antibodies (ie, ipilimumab) in a review of 68 case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). Cases of autoimmune <b>pure red cell aplasia, </b>
<b>neutropenia</b>, <b>thrombocytopenia</b>, and <b>pancytopenia</b> have also been reported with anti-PD-1 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28746020','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28746020','lexi-content-ref-34172516'])">Ref</a></span>). <b>Hemophagocytic lymphohistiocytosis</b> has been reported in patients receiving immunotherapy with pembrolizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025343','lexi-content-ref-30828042','lexi-content-ref-28368439']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025343','lexi-content-ref-30828042','lexi-content-ref-28368439'])">Ref</a></span>). This is a rare but potentially fatal syndrome of excessive immune activation resulting in multi-organ failure, including cytopenias and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31046841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31046841'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism unknown. AIHA may be a result of augmenting or redirecting patients’ immune surveillance. In addition, it is speculated that the random activation of the immune system results in the formation of autoantibodies, activation of T‐cell clones, and the lessening of regulatory T-cell function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). This is different from other drug-induced AIHA where a drug is absorbed to the red blood cell membrane and triggers the development of autoantibodies to the red cell membrane (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; AIHA occurred between 2 and 78 weeks with a median of 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>). Median time to onset has been reported: Neutropenia (10 weeks), autoimmune hemolytic anemia (3.9 weeks), pancytopenia or aplastic anemia (21.7 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30528137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30528137'])">Ref</a></span>), hemophagocytic lymphohistiocytosis (26 days), immune thrombocytopenia (41 days), pure red cell aplasia (89 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Combination immunotherapy and chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30347480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30347480'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>hepatitis</b> (grades 2 to 4) may occur with pembrolizumab. Hepatitis is associated with <b>increased serum aspartate transaminase</b>, <b>increased serum alanine transaminase</b>, and occasionally <b>hyperbilirubinemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856','lexi-content-ref-31309615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856','lexi-content-ref-31309615'])">Ref</a></span>). Although clinically significant hepatotoxicity occurs infrequently, fatal immune-related liver injury has been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>). Hepatoxicity typically involves a hepatocellular or cholestatic pattern of injury and can range from mild laboratory findings to acute liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28476244','lexi-content-ref-33929376','lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28476244','lexi-content-ref-33929376','lexi-content-ref-29603856'])">Ref</a></span>). Immune-mediated hepatitis ranges in severity from mild to life threatening and has both similarities and differences with idiopathic autoimmune hepatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>). The incidence of immune mediated hepatotoxic effects is lower in patients treated with anti-PD-1 monoclonal antibodies like pembrolizumab in comparison to those treated with anti-CTLA-4 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly dose- and time-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28550712','lexi-content-ref-31309615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28550712','lexi-content-ref-31309615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. Hepatotoxicity typically occurs within 1 to 15 weeks but may be delayed by months or years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Cumulative dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Preexisting autoimmune diathesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Chronic infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Tumor infiltration of the liver parenchyma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Combinations of pembrolizumab with other antineoplastic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27141885','lexi-content-ref-28228726','lexi-content-ref-29603856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27141885','lexi-content-ref-28228726','lexi-content-ref-29603856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Autoimmune liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27141885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27141885'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior exposure to chemotherapy, radiation therapy, transarterial chemoembolization (TACE), or radioembolization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31309615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31309615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>In combination with axitinib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>nephritis</b> has rarely occurred. Although an <b>increased serum creatinine </b>is common, <b>acute kidney injury</b> occurs less frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282937','lexi-content-ref-30746132','lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282937','lexi-content-ref-30746132','lexi-content-ref-28228726'])">Ref</a></span>) and may manifest as acute tubular necrosis, autoimmune reactivation of membranous nephropathy, glomerular disease, prerenal disease, or tubulointerstitial nephritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282937','lexi-content-ref-27113507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282937','lexi-content-ref-27113507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. Increased serum creatinine: 12 to 48 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-30865922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-30865922'])">Ref</a></span>). Acute kidney injury: One study documented a median onset of 13 weeks; case reports of earlier onset of 3 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282937'])">Ref</a></span>). Another study documented a median onset of 9 months (range: 1 to 24 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30746132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30746132'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurologic toxicity is rare and has been reported with use of pembrolizumab alone or in combination with chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726'])">Ref</a></span>). These include <b>cerebral hemorrhage</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28283736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28283736'])">Ref</a></span>), <b>confusion</b>, <b>myasthenia gravis,</b> and <b>reversible posterior leukoencephalopathy syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28228726','lexi-content-ref-26655111','lexi-content-ref-22203769','lexi-content-ref-26371282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28228726','lexi-content-ref-26655111','lexi-content-ref-22203769','lexi-content-ref-26371282'])">Ref</a></span>). More common peripheral nervous adverse reactions include <b>peripheral neuropathy</b> and <b>Guillain-Barre syndrome</b>. More common CNS adverse reactions include <b>aseptic meningitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31781445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31781445'])">Ref</a></span>), <b>encephalitis</b>, and transverse myelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28426103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28426103'])">Ref</a></span>). Fatal reversible posterior leukoencephalopathy syndrome with intraventricular hemorrhage occurred in one patient in endometrial cancer clinical trials with pembrolizumab and lenvatinib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22203769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22203769'])">Ref</a></span>). Neurologic toxicity may be fatal or cause permanent impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; typically develop within 3 to 4 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516','lexi-content-ref-28426103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516','lexi-content-ref-28426103'])">Ref</a></span>). Guillain-Barre syndrome: Onset typically within the first 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ophthalmic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis</b> (anterior, posterior, or panuveitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)) has been reported in patients receiving both single agent and combination anti-PD-1 and anti-CTLA-4 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371282','lexi-content-ref-25891173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371282','lexi-content-ref-25891173'])">Ref</a></span>). Other ocular reactions reported include blurred vision, <b>dry eye syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>), color changes, ocular <b>myasthenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31528768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31528768'])">Ref</a></span>), photophobia (associated with aseptic meningitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31781445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31781445'])">Ref</a></span>), inflammation of the eyelid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30865922','lexi-content-ref-27084345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30865922','lexi-content-ref-27084345'])">Ref</a></span>), <b>optic neuritis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32998608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32998608'])">Ref</a></span>), <b>optic papillitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32243282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32243282'])">Ref</a></span>), <b>retinal detachment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32243282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32243282'])">Ref</a></span>), <b>Vogt-Koyanagi-Harada disease</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29730378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29730378'])">Ref</a></span>), and <b>vision loss</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30997872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30997872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; median onset of 5 weeks (range: 1 to 72 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immune-mediated <b>pneumonitis</b> has occurred less frequently, including grade 3 and 4 and fatal cases. Pneumonitis was found to be more common with anti-PD-1 monoclonal antibodies compared to anti-PD-L1 monoclonal antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499515'])">Ref</a></span>). Recurrent pneumonitis following resolution of symptoms has occurred in patients who were re-challenged with immune checkpoint inhibitor therapy and in patients who were not re-challenged; chronic courses may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median onset of ~3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior thoracic radiation in non-small cell lung cancer patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment-naive patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28499515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28499515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asthma and/or smoking (higher grade) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment for non-small cell lung cancer or renal cell carcinoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F26125002"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence of adverse reactions include unapproved dosing regimens.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (4% to 11%), peripheral edema (11% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (11% to 28%), skin rash (13% to 30%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Skin Rash</span>, vitiligo (13%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Vitiligo table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-vitiligo" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-vitiligo')">table 2</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Vitiligo</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Skin Rash" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-refractory melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">357</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">70% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23% (Ipilimumab)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8% (Docetaxel)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated non–small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">682</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">309</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Vitiligo" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-vitiligo" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Vitiligo</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2% (Ipilimumab)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">256</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum bicarbonate (22%), hypercalcemia (14% to 22%), hypercholesterolemia (20%), hyperglycemia (38% to 59%), hyperkalemia (13% to 28%), hyperthyroidism (3% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Hyperthyroidism table link" class="lexi-table-link" data-table-id="lexi-content-hyperthyroidism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperthyroidism')">table 3</a>)</span><span class="table-link" style="display:none;">Hyperthyroidism</span>, hypertriglyceridemia (33% to 43%), hypoalbuminemia (16% to 44%), hypocalcemia (15% to 27%), hypoglycemia (13% to 19%), hypokalemia (15% to 20%), hypomagnesemia (16% to 25%), hyponatremia (10% to 46%), hypophosphatemia (19% to 31%), hypothyroidism (8% to 22%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Hypothyroidism table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-hypothyroidism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-hypothyroidism')">table 4</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Hypothyroidism</span>, weight loss (10% to 15%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperthyroidism" frame="border" id="lexi-content-hyperthyroidism" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Hyperthyroidism</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Resected non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">580</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">581</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Hypothyroidism" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-hypothyroidism" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Hypothyroidism</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cervical cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6% (Cetuximab platinum FU)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2% (Chemotherapy)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Primary mediastinal large B-cell lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3% (Brentuximab vedotin)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Resected non-small cell lung cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">580</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">581</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11% to 23%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-abdominal-pain')">table 5</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Abdominal Pain</span>, constipation (12% to 22%), decreased appetite (15% to 25%), diarrhea (12% to 28%; grades 3/4: ≤3%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-diarrhea')">table 6</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Diarrhea</span>, nausea (11% to 22%; grades 3/4: ≤1%), vomiting (infants, children, adolescents: 29%; adults: 11% to 19%; grades 3/4: ≤1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Abdominal Pain" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants ≥6 months, children, and adolescents ≤17 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced melanoma, lymphoma, or PD-L1 positive solid tumors</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-refractory melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">357</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cervical cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Diarrhea" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-refractory melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">357</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">17% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (12% to 19%), urinary tract infection (2% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (17% to 54%; grades 3/4: 0.5% to 24%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Anemia table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-anemia')">table 7</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Anemia</span>, hemorrhage (19%; grades 3/4: 5%; major hemorrhage: 4%), increased INR (19% to 27%; grades 3/4: ≤2%), leukopenia (31% to 35%; grades 3/4: 9%), lymphocytopenia (infants, children, adolescents: 13%; adults: 24% to 54%; grades 3/4: 1% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Lymphocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-lymphocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-lymphocytopenia')">table 8</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Lymphocytopenia</span>, neutropenia (7% to 30%; grades 3/4: 1% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-neutropenia')">table 9</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Neutropenia</span>, prolonged partial thromboplastin time (14%), thrombocytopenia (12% to 34%; grades 3/4: 4% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Thrombocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-thrombocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-thrombocytopenia')">table 10</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Thrombocytopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Anemia" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-anemia" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants ≥6 months, children, and adolescents ≤17 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced melanoma, lymphoma, or PD-L1 positive solid tumors</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 54%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cervical cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cervical cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 52%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">33% (Ipilimumab)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4% (Ipilimumab)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 52%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">68% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">79% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">33% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Lymphocytopenia" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-lymphocytopenia" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Lymphocytopenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants ≥6 months, children, and adolescents ≤17 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced melanoma, lymphoma, or PD-L1 positive solid tumors</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 54%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">74% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25% (Ipilimumab)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6% (Ipilimumab)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 45%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">53% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">41% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Neutropenia" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants ≥6 months, children, and adolescents ≤17 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced melanoma, lymphoma, or PD-L1 positive solid tumors</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">71% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary mediastinal large B-cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary mediastinal large B-cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">17% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Thrombocytopenia" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-thrombocytopenia" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Thrombocytopenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infants ≥6 months, children, and adolescents ≤17 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Advanced melanoma, lymphoma, or PD-L1 positive solid tumors</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 34%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (10% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Hyperbilirubinemia table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-hyperbilirubinemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-hyperbilirubinemia')">table 11</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Hyperbilirubinemia</span>, increased serum alanine aminotransferase (20% to 34%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-increased-serum-alanine-aminotransferase')">table 12</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase</span>, increased serum alkaline phosphatase (17% to 42%), increased serum aspartate aminotransferase (20% to 39%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-increased-serum-aspartate-aminotransferase')">table 13</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Hyperbilirubinemia" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-hyperbilirubinemia" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Hyperbilirubinemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hepatocellular carcinoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9% (Brentuximab vedotin)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-refractory melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">357</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9% (Docetaxel)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">682</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">309</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-increased-serum-aspartate-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-refractory melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">357</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of resected melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">509</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">502</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">37% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25% (Ipilimumab)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 or 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-naive melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">555</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12% (Docetaxel)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">682</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">309</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously untreated non-small cell lung cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">636</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">615</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">41% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (16%; serious infection: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (10% to 11%), fatigue (20% to 43%), headache (infants, children, adolescents: 25%; adults: 11% to 15%), pain (22%), peripheral neuropathy (1% to 11%; grades 3/4: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Peripheral Neuropathy table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-peripheral-neuropathy" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-peripheral-neuropathy')">table 14</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Peripheral Neuropathy</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Peripheral Neuropathy" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-peripheral-neuropathy" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Peripheral Neuropathy</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg/kg or 10 mg/kg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ipilimumab-refractory melanoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">357</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10% to 18%), back pain (11% to 12%), musculoskeletal pain (19% to 41%), myalgia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (2% to 13%), increased serum creatinine (11% to 40%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Increased Serum Creatinine table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-increased-serum-creatinine" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-increased-serum-creatinine')">table 15</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Increased Serum Creatinine</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Increased Serum Creatinine" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-increased-serum-creatinine" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Increased Serum Creatinine</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of renal cell carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">488</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27% (Cetuximab platinum FU)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28% (Chemotherapy)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Previously treated urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">255</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14% (Brentuximab vedotin)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Relapsed or refractory classical Hodgkin lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Urothelial carcinoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (14% to 26%), dyspnea (10% to 23%), flu-like symptoms (11%), pneumonia (3% to 12%), pneumonitis (2% to 11%), upper respiratory tract infection (13% to 41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10% to 33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (2%), cardiac tamponade (2%), ischemic heart disease (2%), myocarditis (≤1%), pericardial effusion (2%), pericarditis (2% to 4%), pulmonary embolism (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (1%), diabetic ketoacidosis (1%), thyroiditis (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (2%), dysphagia (8%), stomatitis (3%)<span class="lexi-table-link-container"> (<a aria-label="Pembrolizumab: Adverse Reaction: Stomatitis table link" class="lexi-table-link" data-table-id="lexi-content-pembrolizumab-adverse-reaction-stomatitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pembrolizumab-adverse-reaction-stomatitis')">table 16</a>)</span><span class="table-link" style="display:none;">Pembrolizumab: Adverse Reaction: Stomatitis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pembrolizumab: Adverse Reaction: Stomatitis" frame="border" id="lexi-content-pembrolizumab-adverse-reaction-stomatitis" rules="all">
<caption style="text-align:center;">
<b>Pembrolizumab: Adverse Reaction: Stomatitis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pembrolizumab)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">All grades: 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28% (Cetuximab platinum FU)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4% (Cetuximab platinum FU)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg every 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First-line treatment of metastatic or unresectable, recurrent head and neck squamous cell cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (1%), tumor flare (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (grades 3/4: 8%), hepatitis (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (10%), infusion-related reaction (≤9%; including severe infusion-related reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection (9%), herpes zoster infection (≥1%), sepsis (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered mental status (3%), confusion (≥2%), dizziness (5%), insomnia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (2%), myositis (≤1%), neck pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Uveitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (10%), oropharyngeal pain (8%), pleural effusion (2%), respiratory failure (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fistula (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoparathyroidism, hypophysitis, type 1 diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Duodenitis, gastritis, increased serum amylase, increased serum lipase, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hemolytic anemia, hemophagocytic lymphohistiocytosis, immune thrombocytopenia, lymphadenitis (histiocytic necrotizing lymphadenitis [Kikuchi lymphadenitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Organ transplant rejection (solid), sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Systemic inflammatory response syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Demyelinating disease, encephalitis, Guillain-Barre syndrome, meningitis, myasthenia (myasthenic syndrome), myasthenia gravis (including exacerbation of myasthenia gravis), neuropathy (autoimmune), paresis (nerve)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myelitis, polymyalgia rheumatica, polymyositis, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephritis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile-</i>associated diarrhea, rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection with sepsis, uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Graft versus host disease</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis, septic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteomyelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, hemoptysis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome (Ni 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (Hara 2020), lichenoid eruption (including lichenoid dermatitis and lichen planus) (Bansal 2023, Emonet 2023, Park 2023), psoriasis flare (Gargiulo 2023), purpuric dermatitis (Oyeku 2023), pyoderma gangrenosum (Tsibris 2021), Stevens-Johnson syndrome (Haratake 2018), toxic epidermal necrolysis (Ran Cai 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis (SITC [Brahmer 2021]), cholecystitis (SITC [Brahmer 2021]), esophagitis (SITC [Brahmer 2021]), gastrointestinal perforation (Beck 2019), hemorrhagic gastritis (Mathialagan 2023), sclerosing cholangitis (Matsumoto 2020, Ooi 2020), xerostomia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (non-bacterial) (He 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Okuzumi 2023), disseminated intravascular coagulation (Alberti 2020), pancytopenia (Atwal 2017), pure red cell aplasia (SITC [Brahmer 2021]; Meri-Abad 2021), thrombotic thrombocytopenic purpura (Nelson 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome (Sackstein 2021), drug reaction with eosinophilia and systemic symptoms (Lamiaux 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Dermatomyositis (Takatsuki 2021), Sjögren disease (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cytomegalovirus disease (Kim 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Lima 2019), cerebral hemorrhage (Yamazaki 2017), chronic inflammatory demyelinating polyneuropathy (Maleissye 2016), demyelinating disease of the central nervous system (neuromyelitis optica spectrum disorder) (Hirano 2022), retrobulbar neuritis (optic) (Kawakado 2021), reversible posterior leukoencephalopathy syndrome (LaPorte 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lambert-Eaton syndrome (exacerbation) (Takigawa 2023), subacute cutaneous lupus erythematosus (Blakeway 2019), systemic sclerosis (Farrugia 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome (SITC [Brahmer 2021]), maculopathy (acute exudative polymorphous vitelliform maculopathy [AEPVM]) (Lambert 2021), optic neuritis (Makri 2022), optic neuropathy (Daetwyler 2023), optic papillitis (de Vries 2022), retinal detachment (serous) (de Vries 2022), retinopathy (Sakai 2023), vision loss (Telfah 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Focal segmental glomerulosclerosis (Kim 2021), glomerulonephritis (necrotizing) (Uner 2021), interstitial nephritis (Peláez Bejarano 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Reactivated tuberculosis (ileitis) (Lau 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Vogt-Koyanagi-Harada disease (Tamura 2018)</p></div>
<div class="block coi drugH1Div" id="F25808627"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to pembrolizumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F25857268"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse reactions (immune-mediated): PD-1/PD-L1 blockers (including pembrolizumab) remove immune response inhibition, thus potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Severe and fatal immune-mediated adverse reactions may occur in any organ system or tissue. Reactions generally occur during treatment (may occur at any time after pembrolizumab initiation); reactions may also occur after pembrolizumab discontinuation. Early identification and management of immune-mediated adverse reactions are necessary to ensure safe use of pembrolizumab. If suspected immune-mediated reactions occur, initiate appropriate workup to exclude alternative causes (including infection). Medically manage immune-mediated adverse reactions promptly and refer for specialty consultation as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions (including severe and life-threatening cases) have occurred. Signs/symptoms of a reaction included rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorders: Anti-PD-1 monoclonal antibodies generate an immune response that may aggravate underlying autoimmune disorders or prior immune-related adverse events. A retrospective study analyzed the safety and efficacy of treatment with anti-PD-1 monoclonal antibodies (eg, pembrolizumab, nivolumab) in melanoma patients with preexisting autoimmune disease or prior significant ipilimumab-mediated adverse immune events. Results showed that while immune toxicities associated with this class of therapy did occur, most reactions were mild and easily manageable and did not require permanent drug therapy discontinuation. A significant percentage of patients achieved clinical response with anti-PD-1 monoclonal antibody therapy, despite baseline autoimmunity or prior ipilimumab-related adverse events (Menzies 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematopoietic cell transplant: Fatal and other serious complications may occur in patients who receive allogeneic hematopoietic cell transplant (HCT) before or after treatment with an anti-PD-L1/PD-1 monoclonal antibody. Transplant-related complications included hyperacute graft-versus-host disease (GVHD), acute or chronic GVHD, hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome) after reduced-intensity conditioning, and steroid-requiring febrile syndrome (with no identified infectious etiology). These complications may occur despite intervening therapy between PD-L1/PD-1 blockade and HCT. Manage early signs/symptoms of transplant-related complications promptly. Assess the risks/benefits of treatment with an anti-PD-L1/PD-1 monoclonal antibody prior to or after an allogenic HCT.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: An increase in mortality was noted in 2 clinical studies in patients with multiple myeloma who received pembrolizumab in combination with a thalidomide analogue and dexamethasone. Pembrolizumab should not be used to treat multiple myeloma in combination with a thalidomide analogue and dexamethasone unless as part of a clinical trial.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Checkpoint inhibitors may worsen or precipitate new myasthenia gravis (MG), especially within the first 16 weeks of treatment; use with caution. Patients with well-controlled MG may be considered for checkpoint inhibitor therapy if MG treatment is maintained (or reinitiated in patients whose MG is in remission), combination therapy (eg, anti-CTLA-4 with anti-PD-a/PD-L1 monoclonal antibodies) is avoided, and respiratory and bulbar function are closely followed. In patients who develop overt MG during checkpoint inhibitor therapy, early aggressive treatment with plasma exchange or IVIG in combination with high-dose corticosteroids may be required (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Patients ≥75 years of age experienced higher incidences of fatal adverse reactions with pembrolizumab (in combination with enfortumab vedotin for the treatment of locally advanced or metastatic urothelial cancer) compared to patients &lt;75 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and kidney and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Some indications are based on PD-L1 expression, or are based on tumor specimen microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), mismatch repair proficient (pMMR), or tumor mutational burden-high (TMB-H) status. Information on approved tests for patient selection may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=96957" target="_blank">http://www.fda.gov/companiondiagnostics</a>. Because subclonal dMMR mutations and microsatellite instability may arise in high-grade gliomas during temozolomide therapy, it is recommended to test for TMB-H, MSI-H, or dMMR in the primary tumor specimens obtained prior to temozolomide initiation (in patients with high-grade gliomas). Due to discordance between local tests and approved tests, in patients with MSI-H or dMMR noncolorectal cancer solid tumors, if feasible, confirmation of MSI-H or dMMR status is recommended by an approved test; if unable to perform confirmatory MSI-H/dMMR testing, may select patients for treatment by determining the presence of TMB ≥10 mutations/megabase via an approved test.</p></div>
<div class="block foc drugH1Div" id="F25871641"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keytruda: 100 mg/4 mL (4 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F25871639"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26116586"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Keytruda Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/4 mL (per mL): $1,667.26</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871807"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keytruda: 100 mg/4 mL (4 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F25860614"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 30 minutes through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do not infuse other medications through the same infusion line.</p>
<p style="text-indent:-2em;margin-left:2em;">Interrupt or slow the infusion for grade 1 or 2 infusion-related reactions; permanently discontinue for grade 3 or 4 infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Biliary tract cancer (locally advanced unresectable or metastatic), esophageal cancer (locally advanced or metastatic), gastric cancer (locally advanced or metastatic, HER2-negative), head and neck squamous cell carcinoma (unresectable/recurrent, metastatic), non–small cell lung cancer (resectable or metastatic), and triple-negative breast cancer (high-risk, early stage<b> or</b> locally recurrent unresectable or metastatic):</i> When administered in combination with chemotherapy, administer pembrolizumab prior to chemotherapy when administered on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Cervical cancer (stage III to IVA or persistent, recurrent, or metastatic): </i>When administered in combination with chemoradiotherapy or chemotherapy with or without bevacizumab, administer pembrolizumab prior to chemoradiotherapy or prior to chemotherapy (± bevacizumab) when administered on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Gastric cancer (locally advanced or metastatic, HER2-positive): </i>When administered in combination with trastuzumab and chemotherapy, administer pembrolizumab prior to trastuzumab and chemotherapy when administered on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Urothelial cancer (locally advanced or metastatic): </i>When administered in combination with enfortumab vedotin, administer pembrolizumab after enfortumab vedotin (when administered on the same day). In the clinical trial, when both were administered on the same day, pembrolizumab was administered ~30 minutes after enfortumab vedotin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36041086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36041086'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614569"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Infuse over 30 minutes through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do not infuse other medications through the same infusion line.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reaction: </b>Interrupt or slow the infusion for grade 1 or 2 infusion-related reactions; permanently discontinue for grade 3 or 4 infusion-related reactions.</p></div>
<div class="block meg drugH1Div" id="F26116099"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:2em;">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Keytruda: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125514s151s152lbl.pdf%23page%3D150&amp;token=ML9f4%2BOWP20VGzMUEq3Y%2FP7d0xsO9cRfwnNJu0jocszycNcNXbsXh4KpKG6TUSXJblE9yejxJ9E2NLU1HoyaElGkHnx9WxYfFKpkJCpV%2BDkdU5OGKpGMNjP7u0XPTivn&amp;TOPIC_ID=96957" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s151s152lbl.pdf#page=150</a></p></div>
<div class="block use drugH1Div" id="F25808626"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, locally advanced unresectable or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with cisplatin and gemcitabine) of locally advanced unresectable or metastatic biliary tract cancer (BTC).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, triple-negative:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of high-risk early-stage triple-negative breast cancer as neoadjuvant therapy (in combination with chemotherapy), and then continued as adjuvant therapy (as a single agent) following surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with chemotherapy) of locally recurrent unresectable or metastatic triple-negative breast cancer in patients whose tumors express PD-L1 (combined positive score [CPS] ≥10) as determined by an approved test.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with chemoradiotherapy) of FIGO 2014 stage III to IVA cervical cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with chemotherapy, with or without bevacizumab) of persistent, recurrent, or metastatic cervical cancer in patients whose tumors express PD-L1 (CPS ≥1), as determined by an approved test.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single agent) of recurrent or metastatic cervical cancer in patients with disease progression on or after chemotherapy and whose tumors express PD-L1 (CPS ≥1), as determined by an approved test.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous squamous cell carcinoma, recurrent, metastatic, or locally advanced:</b> Treatment of recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with lenvatinib) of advanced endometrial carcinoma that is mismatch repair proficient (pMMR) (as determined by an approved test), or not microsatellite instability-high (MSI-H), in patients with disease progression following prior systemic therapy (in any setting) and are not candidates for curative surgery or radiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single agent) of advanced endometrial carcinoma that is MSI-H or mismatch repair deficient (dMMR) (as determined by an approved test) in patients with disease progression following prior systemic therapy (in any setting) and are not candidates for curative surgery or radiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, locally advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with platinum- and fluoropyrimidine-based chemotherapy) of locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single agent) of locally advanced or metastatic esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation after ≥1 prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an approved test.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, locally advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy) of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1 (CPS ≥1), as determined by an approved test.</p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with fluoropyrimidine- and platinum-containing chemotherapy) of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer, squamous cell, recurrent or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with platinum and fluorouracil) of metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).</p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (as a single agent) of metastatic or unresectable, recurrent HNSCC in patients whose tumors express PD-L1 (CPS ≥1), as determined by an approved test.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single agent) of recurrent or metastatic HNSCC in patients with disease progression on or after platinum-containing chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, advanced: </b>Treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, classical, relapsed or refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory classical Hodgkin lymphoma (cHL) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of pediatric patients with refractory cHL or with cHL that has relapsed after 2 or more lines of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of stage IIB, IIC, or III melanoma following complete resection in adults and pediatric patients ≥12 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of unresectable or metastatic melanoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, recurrent locally advanced or metastatic:</b> Treatment of recurrent locally advanced or metastatic Merkel cell carcinoma in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Microsatellite instability-high or mismatch repair-deficient cancer, unresectable or metastatic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Solid tumors:</i> Treatment of unresectable or metastatic MSI-H or dMMR solid tumors (as determined by an approved test) in adult and pediatric patients with progression following prior treatment and with no satisfactory alternate treatment options.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Colorectal cancer:</i> Treatment of unresectable or metastatic MSI-H or dMMR (as determined by an approved test) colorectal cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment (as a single agent) of stage IB (T2a ≥4 cm), II, or IIIA non<b>–</b>small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (as a single agent) of NSCLC in patients with stage III NSCLC (who are not candidates for surgical resection or definitive chemoradiation) or in patients with metastatic NSCLC, <b>and</b> PD-L1 expression (tumor proportion score [TPS] ≥1%), as determined by an approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.</p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with pemetrexed and platinum chemotherapy) of metastatic nonsquamous NSCLC in patients with no EGFR or ALK genomic tumor aberrations.</p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with carboplatin and either paclitaxel or paclitaxel [protein bound]) of metastatic squamous NSCLC.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of resectable NSCLC (tumors ≥4 cm or node positive) in adults as neoadjuvant treatment (in combination with platinum-containing chemotherapy), and then continued as adjuvant treatment (as a single agent) after surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single agent) of metastatic NSCLC in patients with PD-L1 expression (TPS ≥1%), as determined by an approved test, and with disease progression on or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression (on approved EGFR- or ALK-directed therapy) prior to receiving pembrolizumab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary mediastinal large B-cell lymphoma, relapsed or refractory:</b> Treatment of primary mediastinal large B-cell lymphoma (PMBCL) in adult and pediatric patients with refractory disease or who have relapsed after 2 or more prior lines of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitation of use: Pembrolizumab is not recommended for treatment of PMBCL in patients who require urgent cytoreductive therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma: </b></p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment (in combination with axitinib or in combination with lenvatinib) of advanced renal cell carcinoma.</p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of renal cell carcinoma in patients at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tumor mutational burden-high cancer, unresectable or metastatic: </b>Treatment of unresectable or metastatic tumor mutational burden-high solid tumors (TMB-H; ≥10 mutations/megabase [mut/Mb]; as determined by an approved test) in adult and pediatric patients who have progressed following prior treatment and have no satisfactory alternative treatment options.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitation of use: Safety and efficacy in pediatric patients with TMB-H CNS cancers have not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single-agent) of Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors in patients who are ineligible for or have elected not to undergo cystectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single-agent) of locally advanced or metastatic urothelial cancer in patients who are not eligible for any platinum-containing chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single-agent) of locally advanced or metastatic urothelial cancer in patients with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with enfortumab vedotin) of locally advanced or metastatic urothelial cancer in adults.</p></div>
<div class="block off-label drugH1Div" id="F54268921"><span class="drugH1">Use: Off-Label: Adult</span><p>Malignant pleural mesothelioma, relapsed or refractory, with PD-L1 expression; Melanoma, advanced, high-risk, resectable, neoadjuvant regimen; Mycosis fungoides/Sézary syndrome, relapsed or refractory; Renal cell carcinoma, advanced, first-line single-agent therapy</p></div>
<div class="block mst drugH1Div" id="F25857263"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pembrolizumab may be confused with atezolizumab, dostarlimab, durvalumab, necitumumab, nivolumab, palivizumab, panitumumab, pemetrexed, pemigatinib, polatuzumab vedotin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F25882853"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F25882850"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: May enhance the hepatotoxic effect of Pembrolizumab.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies) may enhance the hepatotoxic effect of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide Analogues: Pembrolizumab may enhance the adverse/toxic effect of Thalidomide Analogues. Specifically, mortality may be increased when this combination is used for treatment of refractory multiple myeloma. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49309256"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to initiation of pembrolizumab treatment in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 4 months after the last pembrolizumab dose.</p></div>
<div class="block pri drugH1Div" id="F25857265"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pembrolizumab crosses the placenta (Baarslag 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Pembrolizumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of pembrolizumab during pregnancy are limited (Anami 2021; Baarslag 2023; Mittra 2021; Polnaszek 2021). Based on the mechanism of action, in utero exposure to pembrolizumab may cause fetal harm; an alteration in the immune response or immune mediated disorders may develop following in utero exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Immune-mediated colitis may occur during treatment with pembrolizumab. Immune-mediated colitis requiring long term treatment (including corticosteroids and infliximab) has been reported in an infant born at 37 weeks' gestation following exposure to pembrolizumab between 16 and 34 weeks' gestation. Symptoms of colitis occurred 4 months after birth. Pembrolizumab was measurable in the infant plasma at 4.5 months of age (Baarslag 2023).</p>
<p style="text-indent:0em;margin-top:2em;">The use of immune checkpoint inhibitors, including pembrolizumab, has been reported for treatment resistant gestational trophoblastic neoplasia (Braga 2023; Ghorani 2017; Niimi 2023; Wang 2023). Although use may be considered, specific recommendations are not available (SOGC [Eiriksson 2021]). Additional research is needed; studies are ongoing (Wang 2023).</p></div>
<div class="block brc drugH1Div" id="F25857267"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pembrolizumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Pembrolizumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during therapy and for 4 months following the last pembrolizumab dose.</p></div>
<div class="block mop drugH1Div" id="F25860616"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">PD-L1 expression (where applicable); tumor specimen microsatellite instability-high (MSI-H) status, mismatch repair deficient (dMMR) status, mismatch repair proficient status, and/or tumor mutational burden-high (TMB-H) status (where applicable).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor LFTs (AST, ALT, and total bilirubin; at baseline and periodically during treatment; consider monitoring more frequently in patients receiving pembrolizumab/axitinib); kidney function (serum creatinine; at baseline and periodically during treatment); thyroid function (at baseline, periodically during treatment and as clinically indicated); monitor blood glucose (for hyperglycemia); CBC with differential (in patients with Hodgkin lymphoma or primary mediastinal large B-cell lymphoma). Monitor blood cortisol at baseline, prior to surgery, and as clinically indicated (in patients with triple-negative breast cancer receiving neoadjuvant pembrolizumab). Evaluate pregnancy status (prior to initiation of pembrolizumab treatment in patients who can become pregnant). Monitor closely for signs/symptoms of immune-mediated adverse reactions, including adrenal insufficiency, diarrhea/colitis (consider initiating or repeating infectious workup in patients with corticosteroid-refractory immune-mediated colitis to exclude alternative causes), dermatologic toxicity, diabetes mellitus, hypophysitis, ocular disorders, thyroid disorders, pneumonitis and other immune-mediated adverse reactions. Monitor for signs/symptoms of infusion-related reactions. If received/receiving hematopoietic cell transplant, monitor closely for early signs/symptoms of transplant-related complications.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Obtain baseline ECG, natriuretic peptides, and troponins in all patients; obtain a baseline echocardiogram in high-risk patients; consider serial ECGs and cardiac troponins prior to doses 2, 3, and 4, and if normal, reduce to every 3 doses until completion of therapy; cardiovascular risk assessment every 6 to 12 months in high-risk patients who require long-term therapy (&gt;12 months therapy, consider cardiovascular risk assessment every 6 to 12 months in all patients requiring long-term therapy) (ESC [Lyon 2022]). Refer to a cardiologist when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional suggested monitoring (ASCO [Schneider 2021):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to therapy:</i> CBC with differential, serum chemistries, creatine kinase, comprehensive clinical assessment including performance status, weight, BMI, heart rate, BP, and oxygen saturation; consider chest x-ray, ECG, and CT scan; assess history of autoimmune conditions, organ-specific disease, endocrinopathies, neuropathy, and infectious disease; assess bowel habits, respiratory symptoms, skin (for rash), arthralgias, and neurologic symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>During therapy:</i> Assess BP, weight, heart rate, and oxygen saturation; assess for infections, screen for hyperglycemia/diabetes (polyuria, polydipsia, weight loss); eye exam (including intraocular pressure after 6 weeks), CBC with differential, serum chemistries, and creatine kinase; monitor bone mineral density (with long-term therapy).</p></div>
<div class="block pha drugH1Div" id="F25857273"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pembrolizumab is a highly selective anti-PD-1 humanized monoclonal antibody which inhibits programmed cell death-1 (PD-1) activity by binding to the PD-1 receptor on T-cells to block PD-1 ligands (PD-L1 and PD-L2) from binding. Blocking the PD-1 pathway inhibits the negative immune regulation caused by PD-1 receptor signaling (Hamid 2013). Anti-PD-1 antibodies (including pembrolizumab) reverse T-cell suppression and induce antitumor responses (Robert 2014).</p></div>
<div class="block phk drugH1Div" id="F25857275"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> With weight-based dosing (2 mg/kg) every 3 weeks, pembrolizumab concentrations in pediatric patients are comparable to those of adults (at the same dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 22 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: First dose: 252 mL/day; steady state: 195 mL/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45649755"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Keytruda | Kitruda</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Keytruda</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32418466">
<a name="32418466"></a>Alberti A, Mancin M, Cortinovis D, Bidoli P, Sala L. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab. Immunotherapy. 2020;12(9):629-633. doi:10.2217/imt-2020-0018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32418466/pubmed" id="32418466" target="_blank">32418466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28476244">
<a name="28476244"></a>Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. <i>Clin Radiol</i>. 2017;72(7):521-533. doi:10.1016/j.crad.2017.04.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28476244/pubmed" id="28476244" target="_blank">28476244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28291584">
<a name="28291584"></a>Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. <i>Lancet Oncol</i>. 2017;18(5):623‐630. doi:10.1016/S1470-2045(17)30169-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28291584/pubmed" id="28291584" target="_blank">28291584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34650809">
<a name="34650809"></a>Anami Y, Minami S, Kumegawa A, et al. Malignant melanoma treated with pembrolizumab during pregnancy: a case report and review of the literature. <i>Mol Clin Oncol</i>. 2021;15(5):242. doi:10.3892/mco.2021.2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34650809/pubmed" id="34650809" target="_blank">34650809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33264544">
<a name="33264544"></a>André T, Shiu KK, Kim TW, et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-Instability-high advanced colorectal cancer. <i>N Engl J Med</i>. 2020;383(23):2207-2218. doi:10.1056/NEJMoa2017699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33264544/pubmed" id="33264544" target="_blank">33264544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609651">
<a name="31609651"></a>Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. <i>J Clin Oncol</i>. 2019;37(34):3291-3299. doi: 10.1200/JCO.19.01389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31609651/pubmed" id="31609651" target="_blank">31609651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28746020">
<a name="28746020"></a>Atwal D, Joshi KP, Ravilla R, Mahmoud F. Pembrolizumab-induced pancytopenia: A case report. <i>Perm J</i>. 2017;21:17-004. doi:10.7812/TPP/17-004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28746020/pubmed" id="28746020" target="_blank">28746020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37937778">
<a name="37937778"></a>Baarslag MA, Heimovaara JH, Borgers JSW, et al. Severe immune-related enteritis after in utero exposure to pembrolizumab. <i>N Engl J Med</i>. 2023;389(19):1790-1796. doi:10.1056/NEJMoa2308135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37937778/pubmed" id="37937778" target="_blank">37937778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051177">
<a name="34051177"></a>Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. <i>Lancet Oncol</i>. 2021;22(7):919-930. doi:10.1016/S1470-2045(21)00147-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34051177/pubmed" id="34051177" target="_blank">34051177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37266094">
<a name="37266094"></a>Bansal A, Singla A, Paul D, Kaur S. Pembrolizumab-induced lichen planus: a rare immune-related adverse side effect. <i>Indian Dermatol Online J</i>. 2023;14(3):391-394. doi:10.4103/idoj.idoj_377_22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37266094/pubmed" id="37266094" target="_blank">37266094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31018834">
<a name="31018834"></a>Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. <i>BMC Cancer</i>. 2019;19(1):379. doi: 10.1186/s12885-019-5577-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31018834/pubmed" id="31018834" target="_blank">31018834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28212060">
<a name="28212060"></a>Bellmunt J, de Wit R, Vaughn DJ, et al; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. <i>N Engl J Med</i>. 2017;376(11):1015-1026. doi: 10.1056/NEJMoa1613683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28212060/pubmed" id="28212060" target="_blank">28212060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30762712">
<a name="30762712"></a>Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. <i>Melanoma Res</i>. 2019;29(3):338-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30762712/pubmed" id="30762712" target="_blank">30762712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27141885">
<a name="27141885"></a>Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nat Rev Clin Oncol</i>. 2016;13(8):473-486. doi:10.1038/nrclinonc.2016.58<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27141885/pubmed" id="27141885" target="_blank">27141885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37523979">
<a name="37523979"></a>Braga A, Balthar E, Souza LCS, et al. Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases. <i>Clinics (Sao Paulo)</i>. 2023;78:100260. doi:10.1016/j.clinsp.2023.100260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37523979/pubmed" id="37523979" target="_blank">37523979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29442540">
<a name="29442540"></a>Brahmer JR, Lacchetti C, Schneider BJ, et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i>. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29442540/pubmed" id="29442540" target="_blank">29442540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31679945">
<a name="31679945"></a>Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [published correction appears in <i>Lancet</i>. 2020;395(10220):272]. <i>Lancet</i>. 2019;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31679945/pubmed" id="31679945" target="_blank">31679945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31810421">
<a name="31810421"></a>Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab. <i>J Oncol Pharm Pract</i>. 2020;26(5):1259-1265. doi:10.1177/1078155219890659.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31810421/pubmed" id="31810421" target="_blank">31810421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26715621">
<a name="26715621"></a>Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Ann Oncol</i>. 2016;27(4):559-574. doi: 10.1093/annonc/mdv623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26715621/pubmed" id="26715621" target="_blank">26715621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27659911">
<a name="27659911"></a>Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. <i>BMJ Case Rep.</i> 2016;2016:bcr2016216426. doi:10.1136/bcr-2016-216426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27659911/pubmed" id="27659911" target="_blank">27659911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28441111">
<a name="28441111"></a>Chen R, Zinzani PL, Fanale MA, et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. <i>J Clin Oncol</i>. 2017;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28441111/pubmed" id="28441111" target="_blank">28441111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31409671">
<a name="31409671"></a>Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i>. 2019;134(14):1144-1153. doi: 10.1182/blood.2019000324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31409671/pubmed" id="31409671" target="_blank">31409671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30298302">
<a name="30298302"></a>Cheun H, Kim M, Lee H, Oh KH, Keam B. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. <i>Invest New Drugs.</i> 2019;37(3):579-583. doi:10.1007/s10637-018-0673-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30298302/pubmed" id="30298302" target="_blank">30298302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34407342">
<a name="34407342"></a>Choueiri TK, Tomczak P, Park SH, et al; KEYNOTE-564 Investigators. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. <i>N Engl J Med.</i> 2021;385(8):683-694. doi:10.1056/NEJMoa2106391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34407342/pubmed" id="34407342" target="_blank">34407342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30943124">
<a name="30943124"></a>Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. <i>J Clin Oncol.</i> 2019;37(17):1470-1478. doi: 10.1200/JCO.18.01265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30943124/pubmed" id="30943124" target="_blank">30943124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34534429">
<a name="34534429"></a>Colombo N, Dubot C, Lorusso D, et al; KEYNOTE-826 Investigators. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. <i>N Engl J Med</i>. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34534429/pubmed" id="34534429" target="_blank">34534429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282937">
<a name="27282937"></a>Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney Int</i>. 2016;90(3):638-647. doi:10.1016/j.kint.2016.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27282937/pubmed" id="27282937" target="_blank">27282937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33278935">
<a name="33278935"></a>Cortes J, Cescon DW, Rugo HS, et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i>. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33278935/pubmed" id="33278935" target="_blank">33278935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35857659">
<a name="35857659"></a>Cortes J, Rugo HS, Cescon DW, et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. <i>N Engl J Med</i>. 2022;387(3):217-226. doi:10.1056/NEJMoa2202809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35857659/pubmed" id="35857659" target="_blank">35857659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37228591">
<a name="37228591"></a>Daetwyler E, Zippelius A, Meyer P, Läubli H. Pembrolizumab-induced optic neuropathy - a case report. <i>Front Immunol</i>. 2023;14:1171981. doi:10.3389/fimmu.2023.1171981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37228591/pubmed" id="37228591" target="_blank">37228591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27468083">
<a name="27468083"></a>de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. <i>N Engl J Med</i>. 2016;375(3):296-297. doi:10.1056/NEJMc1515584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27468083/pubmed" id="27468083" target="_blank">27468083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30528137">
<a name="30528137"></a>Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematol</i>. 2019;6(1):e48-e57. doi:10.1016/S2352-3026(18)30175-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30528137/pubmed" id="30528137" target="_blank">30528137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32243282">
<a name="32243282"></a>de Vries EW, Schauwvlieghe AS, Haanen JB, de Hoog J. Bilateral serous retinal detachment and uveitis associated with pembrolizumab treatment in metastatic melanoma. <i>Retin Cases Brief Rep</i>. 2022;16(4):430-434. doi:10.1097/ICB.0000000000000999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32243282/pubmed" id="32243282" target="_blank">32243282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35427471">
<a name="35427471"></a>Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncol</i>. 2022;23(5):659-670. doi:10.1016/S1470-2045(22)00197-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35427471/pubmed" id="35427471" target="_blank">35427471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29658430">
<a name="29658430"></a>Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma.<i> N Engl J Med.</i> 2018;378(19):1789-1801. doi: 10.1056/NEJMoa1802357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29658430/pubmed" id="29658430" target="_blank">29658430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36622668">
<a name="36622668"></a>Emonet C, Tétart F, Bauvin O, et al. Pustular lichenoid eruptions induced by immune checkpoint inhibitors: two case reports and a review of the literature. <i>J Immunother</i>. 2023;46(2):59-63. doi:10.1097/CJI.0000000000000449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36622668/pubmed" id="36622668" target="_blank">36622668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29158217">
<a name="29158217"></a>Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. <i>Circulation</i>. 2017;136(21):2085-2087. doi:10.1161/CIRCULATIONAHA.117.030571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29158217/pubmed" id="29158217" target="_blank">29158217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31189042">
<a name="31189042"></a>Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. <i>N Engl J Med</i>. 2019;380(24):2375-2376. doi:10.1056/NEJMc1903064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31189042/pubmed" id="31189042" target="_blank">31189042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31528768">
<a name="31528768"></a>Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors.<i> J Curr Ophthalmol</i>. 2019;31(3):319-322. doi:10.1016/j.joco.2019.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31528768/pubmed" id="31528768" target="_blank">31528768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37900813">
<a name="37900813"></a>Farrugia S, Mercieca L, Betts A, Refalo N, Boffa MJ. Scleroderma secondary to pembrolizumab: a case report and review of 19 cases of anti-PD-1-induced scleroderma. <i>Case Rep Oncol</i>. 2023;16(1):846-856. doi:10.1159/000533373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37900813/pubmed" id="37900813" target="_blank">37900813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27367787">
<a name="27367787"></a>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. <i>JAMA Oncol</i>. 2016;2(10):1346-1353. doi:10.1001/jamaoncol.2016.1051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27367787/pubmed" id="27367787" target="_blank">27367787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29802219">
<a name="29802219"></a>Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. <i>Oncologist</i>. 2018;23(8):879-886. doi:10.1634/theoncologist.2018-0130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29802219/pubmed" id="29802219" target="_blank">29802219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29658856">
<a name="29658856"></a>Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. <i>N Engl J Med</i>. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29658856/pubmed" id="29658856" target="_blank">29658856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36728879">
<a name="36728879"></a>Gargiulo L, Ibba L, Valenti M, Costanzo A, Narcisi A. Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma. <i>Melanoma Res</i>. 2023;33(2):152-154. doi:10.1097/CMR.0000000000000875<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36728879/pubmed" id="36728879" target="_blank">36728879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25891174">
<a name="25891174"></a>Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. <i>N Engl J Med</i>. 2015;372(21):2018-2028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/25891174/pubmed" id="25891174" target="_blank">25891174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George D. Systemic therapy of advanced clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29185430">
<a name="29185430"></a>Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. <i>Lancet</i>. 2017;390(10110):2343-2345. doi:10.1016/S0140-6736(17)32894-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29185430/pubmed" id="29185430" target="_blank">29185430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32673170">
<a name="32673170"></a>Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). <i>J Clin Oncol</i>. 2020;38(25):2916-2925. doi:10.1200/JCO.19.03054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32673170/pubmed" id="32673170" target="_blank">32673170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28881921">
<a name="28881921"></a>Haanen JBAG, Carbonnel F, Robert C, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2017;28(suppl_4):iv119-iv142. doi:10.1093/annonc/mdx225. Erratum in: <i>Ann Oncol</i>. 2018;29(Suppl 4):iv264-iv266. Erratum in: <i>Ann Oncol</i>. 2018;29 Suppl 4:iv264-iv266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28881921/pubmed" id="28881921" target="_blank">28881921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23724846">
<a name="23724846"></a>Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>N Engl J Med</i>. 2013;369:134-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/23724846/pubmed" id="23724846" target="_blank">23724846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511479">
<a name="31511479"></a>Hara K, Yamasaki K, Yamada S, Yatera K. Bullous pemphigoid in a patient treated with pembrolizumab.<i> Intern Med</i>. 2020;59(1):139-140. doi:10.2169/internalmedicine.3264-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31511479/pubmed" id="31511479" target="_blank">31511479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29885481">
<a name="29885481"></a>Haratake N, Tagawa T, Hirai F, Toyokawa G, Miyazaki R, Maehara Y. Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient. <i>J Thorac Oncol</i>. 2018;13(11):1798-1799. doi:10.1016/j.jtho.2018.05.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29885481/pubmed" id="29885481" target="_blank">29885481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28550712">
<a name="28550712"></a>Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treat Rev</i>. 2017;57:36-49. doi:10.1016/j.ctrv.2017.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28550712/pubmed" id="28550712" target="_blank">28550712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35687965">
<a name="35687965"></a>He X, Tu R, Zeng S, He Z, Liu S, Fang Y. Non-bacterial cystitis secondary to pembrolizumab: a case report and review of the literature. <i>Curr Probl Cancer</i>. 2022;46(4):100863. doi:10.1016/j.currproblcancer.2022.100863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35687965/pubmed" id="35687965" target="_blank">35687965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26712084">
<a name="26712084"></a>Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i>. 2016;387(10027):1540-1550. doi:10.1016/S0140-6736(15)01281-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26712084/pubmed" id="26712084" target="_blank">26712084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36517738">
<a name="36517738"></a>Hirano S, Kojima A, Nakayama Y, et al. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study. <i>BMC Neurol</i>. 2022;22(1):483. doi:10.1186/s12883-022-02987-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36517738/pubmed" id="36517738" target="_blank">36517738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26951310">
<a name="26951310"></a>Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>J Clin Oncol</i>. 2016;34(13):1510-1517. doi:10.1200/JCO.2015.64.0391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26951310/pubmed" id="26951310" target="_blank">26951310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36041086">
<a name="36041086"></a>Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer.<i> J Clin Oncol</i>. 2023;41(1):22-31. doi:10.1200/JCO.22.01643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36041086/pubmed" id="36041086" target="_blank">36041086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30086678">
<a name="30086678"></a>Hwang A, Iskandar A, Dasanu CA. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. <i>J Oncol Pharm Pract</i>. 2019;25(6):1520-1522. doi:10.1177/1078155218791314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30086678/pubmed" id="30086678" target="_blank">30086678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29764752">
<a name="29764752"></a>Ishizuka S, Sakata S, Yoshida C, et al. Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression. <i>Respir Investig.</i> 2018;56(4):361-364. doi:10.1016/j.resinv.2018.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29764752/pubmed" id="29764752" target="_blank">29764752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30746132">
<a name="30746132"></a>Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab. <i>Clin Kidney J</i>. 2019;12(1):81-88. doi:10.1093/ckj/sfy100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30746132/pubmed" id="30746132" target="_blank">30746132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34912120">
<a name="34912120"></a>Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature.</i> 2021;600(7890):727-730. doi:10.1038/s41586-021-04161-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34912120/pubmed" id="34912120" target="_blank">34912120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37871604">
<a name="37871604"></a>Janjigian YY, Kawazoe A, Bai Y, et al; KEYNOTE-811 Investigators. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. <i>Lancet</i>. Published online October 19, 2023. doi:10.1016/S0140-6736(23)02033-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37871604/pubmed" id="37871604" target="_blank">37871604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27806233">
<a name="27806233"></a>Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. <i>N Engl J Med</i>. 2016;375(18):1749-1755. doi:10.1056/NEJMoa1609214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27806233/pubmed" id="27806233" target="_blank">27806233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28241095">
<a name="28241095"></a>Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. <i>Cancer</i>. 2017;123(11):1904-1911. doi:10.1002/cncr.30642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28241095/pubmed" id="28241095" target="_blank">28241095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32025343">
<a name="32025343"></a>Kalmuk J, Puchalla J, Feng G, Giri A, Kaczmar J. Pembrolizumab-induced hemophagocytic lymphohistiocytosis: an immunotherapeutic challenge. <i>Cancers Head Neck</i>. 2020;5:3. doi:10.1186/s41199-020-0050-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32025343/pubmed" id="32025343" target="_blank">32025343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34148963">
<a name="34148963"></a>Kawakado K, Tamura T, Nakanishi M, Makimoto G, Kuyama S. Retrobulbar Optic Neuritis induced by pembrolizumab in a patient with lung adenocarcinoma. <i>Intern Med</i>. 2021;60(24):3941-3945. doi:10.2169/internalmedicine.7425-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34148963/pubmed" id="34148963" target="_blank">34148963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37075781">
<a name="37075781"></a>Kelley RK, Ueno M, Yoo C, et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i>. 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37075781/pubmed" id="37075781" target="_blank">37075781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keytruda.1">
<a name="Keytruda.1"></a>Keytruda (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; January 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keytruda.2">
<a name="Keytruda.2"></a>Keytruda (pembrolizumab) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532724">
<a name="31532724"></a>Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. <i>J Clin Oncol</i>. 2020;38(1):20-28. doi: 10.1200/JCO.19.01056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31532724/pubmed" id="31532724" target="_blank">31532724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28499515">
<a name="28499515"></a>Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. <i>Chest</i>. 2017;152(2):271-281. doi:10.1016/j.chest.2017.04.177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28499515/pubmed" id="28499515" target="_blank">28499515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34713828">
<a name="34713828"></a>Kim DW, Jeon H, Kim S, et al. Pembrolizumab-induced focal segmental glomerulosclerosis: a case report. <i>Medicine (Baltimore)</i>. 2021;100(43):e27546. doi:10.1097/MD.0000000000027546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34713828/pubmed" id="34713828" target="_blank">34713828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32905211">
<a name="32905211"></a>Kim H, Ha SY, Kim J, Kang M, Lee J. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. <i>Curr Oncol</i>. 2020;27(4):e436-e439. doi:10.3747/co.27.6163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32905211/pubmed" id="32905211" target="_blank">32905211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33026938">
<a name="33026938"></a>Kojima T, Shah MA, Muro K, et al; KEYNOTE-181 Investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer.<i> J Clin Oncol.</i> 2020;38(35):4138-4148. doi:10.1200/JCO.20.01888<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33026938/pubmed" id="33026938" target="_blank">33026938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28228726">
<a name="28228726"></a>Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. <i>Front Pharmacol</i>. 2017;8:49. doi:10.3389/fphar.2017.00049 Erratum in: <i>Front Pharmacol</i>. 2017;8:311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28228726/pubmed" id="28228726" target="_blank">28228726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34090381">
<a name="34090381"></a>Lambert I, Fasolino G, Awada G, Kuijpers R, Ten Tusscher M, Neyns B. Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. <i>BMC Ophthalmol</i>. 2021;21(1):250. doi:10.1186/s12886-021-02011-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34090381/pubmed" id="34090381" target="_blank">34090381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29985833">
<a name="29985833"></a>Lamiaux M, Scalbert C, Lepesant P, et al. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. <i>Melanoma Res</i>. 2018;28(5):451-457. doi:10.1097/CMR.0000000000000472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29985833/pubmed" id="29985833" target="_blank">29985833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27745820">
<a name="27745820"></a>Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncol</i>. 2016;17(11):1497-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27745820/pubmed" id="27745820" target="_blank">27745820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26655111">
<a name="26655111"></a>LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma. <i>J Oncol Pharm Pract</i>. 2017;23(1):71-74. doi:10.1177/1078155215620922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26655111/pubmed" id="26655111" target="_blank">26655111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26027431">
<a name="26027431"></a>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. <i>N Engl J Med</i>. 2015;373(1):23-34. doi:10.1056/NEJMoa1504030. Erratum in: <i>N Engl J Med</i>. 2018;379(22):2185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26027431/pubmed" id="26027431" target="_blank">26027431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34758746">
<a name="34758746"></a>Lau KS, Cheung BM, Lam KO, et al. Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. <i>BMC Infect Dis</i>. 2021;21(1):1148. doi:10.1186/s12879-021-06845-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34758746/pubmed" id="34758746" target="_blank">34758746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31725351">
<a name="31725351"></a>Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite-instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. <i>J Clin Oncol.</i> 2020;38(1):11-19. doi:10.1200/JCO.19.02107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31725351/pubmed" id="31725351" target="_blank">31725351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26028255">
<a name="26028255"></a>Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>N Engl J Med</i>. 2015;372(26):2509-2520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26028255/pubmed" id="26028255" target="_blank">26028255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30005106">
<a name="30005106"></a>Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN, Lo Sicco K. Severe oral mucositis: A rare adverse event of pembrolizumab. <i>J Drugs Dermatol</i>. 2018;17(7):807-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30005106/pubmed" id="30005106" target="_blank">30005106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31781445">
<a name="31781445"></a>Lima G, Kahn A, Sama S, Savage J. Aseptic meningitis as an immune-related adverse event after pembrolizumab. <i>Case Rep Oncol Med</i>. 2019;2019:7183747. doi:10.1155/2019/7183747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31781445/pubmed" id="31781445" target="_blank">31781445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367007">
<a name="35367007"></a>Luke JJ, Rutkowski P, Queirolo P, et al; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet.</i> 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35367007/pubmed" id="35367007" target="_blank">35367007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29567210">
<a name="29567210"></a>Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. <i>J Am Coll Cardiol</i>. 2018;71(16):1755-1764. doi:10.1016/j.jacc.2018.02.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29567210/pubmed" id="29567210" target="_blank">29567210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37058687">
<a name="37058687"></a>Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. <i>J Clin Oncol</i>. 2023;41(16):2904-2910. doi:10.1200/JCO.22.02152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37058687/pubmed" id="37058687" target="_blank">37058687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35045221">
<a name="35045221"></a>Makker V, Colombo N, Casado Herráez A, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. <i>N Engl J Med</i>. 2022;386(5):437-448. doi:10.1056/NEJMoa2108330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35045221/pubmed" id="35045221" target="_blank">35045221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998608">
<a name="32998608"></a>Makri OE, Dimitrakopoulos FI, Tsapardoni F, et al. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. <i>Int J Neurosci</i>. 2022;132(7):643-648. doi:10.1080/00207454.2020.1831489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32998608/pubmed" id="32998608" target="_blank">32998608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32919526">
<a name="32919526"></a>Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.<i> Lancet Oncol.</i> 2020a;21(10):1353-1365. doi:10.1016/S1470-2045(20)30445-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32919526/pubmed" id="32919526" target="_blank">32919526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31682550">
<a name="31682550"></a>Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. <i>J Clin Oncol</i>. 2020b;38(1):1-10. doi:10.1200/JCO.19.02105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31682550/pubmed" id="31682550" target="_blank">31682550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37583508">
<a name="37583508"></a>Mathialagan K, Tai CH, Sethi S, Thomas S, Loeser C. Immune checkpoint inhibitor-induced hemorrhagic gastritis. <i>ACG Case Rep J</i>. 2023;10(8):e01128. doi:10.14309/crj.0000000000001128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37583508/pubmed" id="37583508" target="_blank">37583508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32284868">
<a name="32284868"></a>Matsumoto S, Watanabe K, Kobayashi N, Irie K, Yamanaka S, Kaneko T. Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. <i>Respirol Case Rep</i>. 2020;8(5):e00560. doi:10.1002/rcr2.560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32284868/pubmed" id="32284868" target="_blank">32284868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22203769">
<a name="22203769"></a>Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. <i>J Clin Oncol</i>. 2012;30(6):e76-e78. doi:10.1200/JCO.2011.38.7886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/22203769/pubmed" id="22203769" target="_blank">22203769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33529051">
<a name="33529051"></a>McDermott DF, Lee JL, Bjarnason GA, et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. <i>J Clin Oncol</i>. 2021;39(9):1020-1028. doi:10.1200/JCO.20.02363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33529051/pubmed" id="33529051" target="_blank">33529051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955135">
<a name="29955135"></a>Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>Br J Cancer.</i> 2018;119(2):153-159. doi: 10.1038/s41416-018-0131-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29955135/pubmed" id="29955135" target="_blank">29955135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27687304">
<a name="27687304"></a>Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Ann Oncol</i>. 2017;28(2):368-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27687304/pubmed" id="27687304" target="_blank">27687304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33625098">
<a name="33625098"></a>Meri-Abad M, Cunquero Tomás AJ, Jaime AB. Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review. <i>Melanoma Res</i>. 2021;31(2):186-189. doi:10.1097/CMR.0000000000000724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33625098/pubmed" id="33625098" target="_blank">33625098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30142389">
<a name="30142389"></a>Metaxas Y, Rivalland G, Mauti LA, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. <i>J Thorac Oncol</i>. 2018;13(11):1784‐1791. doi:10.1016/j.jtho.2018.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30142389/pubmed" id="30142389" target="_blank">30142389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34397143">
<a name="34397143"></a>Mittra A, Naqash AR, Murray JH, et al. Outcomes of pregnancy during immunotherapy treatment for cancer: analysis of clinical trials sponsored by the National Cancer Institute. <i>Oncologist</i>. 2021;26(10):e1883-e1886. doi:10.1002/onco.13941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34397143/pubmed" id="34397143" target="_blank">34397143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30955977">
<a name="30955977"></a>Mok TSK, Wu YL, Kudaba I, et al; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i>. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30955977/pubmed" id="30955977" target="_blank">30955977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37910822">
<a name="37910822"></a>Monk BJ, Colombo N, Tewari KS, et al. First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. <i>J Clin Oncol</i>. 2023;41(36):5505-5511. doi:10.1200/JCO.23.00914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37910822/pubmed" id="37910822" target="_blank">37910822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536852">
<a name="29536852"></a>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. <i>Lancet</i>. 2018;391(10124):933. doi:10.1016/S0140-6736(18)30533-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29536852/pubmed" id="29536852" target="_blank">29536852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33616314">
<a name="33616314"></a>Motzer R, Alekseev B, Rha SY, et al; CLEAR Trial Investigators. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. <i>N Engl J Med</i>. 2021;384(14):1289-1300. doi:10.1056/NEJMoa2035716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33616314/pubmed" id="33616314" target="_blank">33616314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26371282">
<a name="26371282"></a>Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Ann Oncol</i>. 2015;26(12):2375-2391. doi:10.1093/annonc/mdv383. Erratum in: <i>Ann Oncol</i>. 2016;27(7):1362.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26371282/pubmed" id="26371282" target="_blank">26371282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35037788">
<a name="35037788"></a>Nelson D, Kodsi M, Cockrell D, Morgan J, Key N. Thrombotic thrombocytopenic purpura associated with pembrolizumab. <i>J Oncol Pharm Pract</i>. 2022;28(4):979-982. doi:10.1177/10781552211073883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35037788/pubmed" id="35037788" target="_blank">35037788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27093365">
<a name="27093365"></a>Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>N Engl J Med</i>. 2016;374(26):2542-2552. doi: 10.1056/NEJMoa1603702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27093365/pubmed" id="27093365" target="_blank">27093365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37746555">
<a name="37746555"></a>Ni H, Ding X, Wu S, Jin X. Case report: clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma. <i>Pathol Oncol Res</i>. 2023;29:1611330. doi:10.3389/pore.2023.1611330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37746555/pubmed" id="37746555" target="_blank">37746555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37679006">
<a name="37679006"></a>Niimi K, Yamamoto E, Oda Y, et al. A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab.<i> Taiwan J Obstet Gynecol.</i> 2023;62(5):745-748. doi:10.1016/j.tjog.2023.07.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37679006/pubmed" id="37679006" target="_blank">37679006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36875060">
<a name="36875060"></a>Nishiyama K, Morikawa K, Shinozaki Y, et al. Case report: electrocardiographic changes in pembrolizumab-induced fatal myocarditis. <i>Front Immunol</i>. 2023;14:1078838. doi:10.3389/fimmu.2023.1078838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36875060/pubmed" id="36875060" target="_blank">36875060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31046841">
<a name="31046841"></a>Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. <i>J Immunother Cancer</i>. 2019;7(1):117. doi:10.1186/s40425-019-0598-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31046841/pubmed" id="31046841" target="_blank">31046841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18545145">
<a name="18545145"></a>Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. <i>Am J Surg Pathol</i>. 2008;32(8):1130-1137. doi:10.1097/PAS.0b013e31817150e3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/18545145/pubmed" id="18545145" target="_blank">18545145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36108662">
<a name="36108662"></a>O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. <i>Lancet Oncol.</i> 2022;23(10):1274-1286. doi:10.1016/S1470-2045(22)00518-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36108662/pubmed" id="36108662" target="_blank">36108662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37369081">
<a name="37369081"></a>O'Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. <i>J Clin Oncol</i>. 2023;41(25):4107-4117. doi:10.1200/JCO.22.02887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37369081/pubmed" id="37369081" target="_blank">37369081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30828042">
<a name="30828042"></a>Okawa S, Kayatani H, Fujiwara K, et al. Pembrolizumab-induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in non-small cell lung cancer. <i>Intern Med</i>. 2019;58(5):699-702. doi:10.2169/internalmedicine.1001-1018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30828042/pubmed" id="30828042" target="_blank">30828042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36450461">
<a name="36450461"></a>Okuzumi S, Kamata H, Emoto K, et al. Successful steroid treatment of pembrolizumab-induced agranulocytosis that developed after splenectomy in a patient with non-small-cell lung cancer. <i>Intern Med</i>. 2023;62(14):2113-2121. doi:10.2169/internalmedicine.0278-22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36450461/pubmed" id="36450461" target="_blank">36450461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34990208">
<a name="34990208"></a>O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. <i>J Clin Oncol.</i> 2022;40(7):752-761. doi:10.1200/JCO.21.01874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34990208/pubmed" id="34990208" target="_blank">34990208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32944497">
<a name="32944497"></a>Ooi R, Tobino K, Sakabe M, et al. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. <i>Respir Med Case Rep</i>. 2020;31:101197. doi:10.1016/j.rmcr.2020.101197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32944497/pubmed" id="32944497" target="_blank">32944497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37009032">
<a name="37009032"></a>Oyeku OJ, Mitchell D, Elwood H, Durkin J. A case of pembrolizumab-induced pigmented purpuric dermatosis. <i>JAAD Case Rep</i>. 2023;34:77-79. doi:10.1016/j.jdcr.2023.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37009032/pubmed" id="37009032" target="_blank">37009032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37332364">
<a name="37332364"></a>Park JJ, Park E, Damsky WE, Vesely MD. Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. <i>JAAD Case Rep</i>. 2023;37:13-15. doi:10.1016/j.jdcr.2023.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37332364/pubmed" id="37332364" target="_blank">37332364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36856617">
<a name="36856617"></a>Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. <i>N Engl J Med</i>. 2023;388(9):813-823. doi:10.1056/NEJMoa2211437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36856617/pubmed" id="36856617" target="_blank">36856617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280635">
<a name="30280635"></a>Paz-Ares L, Luft A, Vicente D, et al; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. <i>N Engl J Med</i>. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30280635/pubmed" id="30280635" target="_blank">30280635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33040674">
<a name="33040674"></a>Peláez Bejarano A, Montero Pérez O, Inoriza Rueda A, Garrido Martínez MT. Interstitial nephritis with pembrolizumab: a case report and review. <i>J Oncol Pharm Pract</i>. 2021;27(4):1046-1051. doi:10.1177/1078155220961553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33040674/pubmed" id="33040674" target="_blank">33040674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259474">
<a name="34259474"></a>Polnaszek B, Mullen M, Bligard K, Raghuraman N, Massad LS. Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy. <i>Obstet Gynecol</i>. 2021;138(1):115-118. doi:10.1097/AOG.0000000000004434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34259474/pubmed" id="34259474" target="_blank">34259474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320654">
<a name="29320654"></a>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. <i>N Engl J Med</i>. 2018;378(2):158-168. doi:10.1056/NEJMra1703481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29320654/pubmed" id="29320654" target="_blank">29320654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33284113">
<a name="33284113"></a>Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2020;21(12):1563-1573. doi:10.1016/S1470-2045(20)30436-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33284113/pubmed" id="33284113" target="_blank">33284113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36055304">
<a name="36055304"></a>Powles T, Tomczak P, Park SH, et al; KEYNOTE-564 Investigators. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.<i> Lancet Oncol</i>. 2022;23(9):1133-1144. doi:10.1016/S1470-2045(22)00487-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36055304/pubmed" id="36055304" target="_blank">36055304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35728020">
<a name="35728020"></a>Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2022;40(25):2957-2995. doi:10.1200/JCO.22.00868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35728020/pubmed" id="35728020" target="_blank">35728020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27718847">
<a name="27718847"></a>Reck M, Rodríguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. <i>N Engl J Med</i>. 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27718847/pubmed" id="27718847" target="_blank">27718847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37875143">
<a name="37875143"></a>Rha SY, Oh DY, Yañez P, et al; KEYNOTE-859 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i>. 2023;24(11):1181-1195. doi:10.1016/S1470-2045(23)00515-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37875143/pubmed" id="37875143" target="_blank">37875143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26115796">
<a name="26115796"></a>Ribas A, Puzanov I, Dummer R, et al, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncol</i>. 2015 Aug;16(8):908-918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26115796/pubmed" id="26115796" target="_blank">26115796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30779529">
<a name="30779529"></a>Rini BI, Plimack ER, Stus V, et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2019;380(12):1116-1127. doi:10.1056/NEJMoa1816714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30779529/pubmed" id="30779529" target="_blank">30779529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25034862">
<a name="25034862"></a>Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i>. 2014;384(9948):1109-1117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/25034862/pubmed" id="25034862" target="_blank">25034862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25891173">
<a name="25891173"></a>Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>N Engl J Med</i>. 2015;372(26):2521-2532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/25891173/pubmed" id="25891173" target="_blank">25891173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34330765">
<a name="34330765"></a>Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. <i>J Immunother Cancer</i>. 2021;9(7):e002855. doi:10.1136/jitc-2021-002855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34330765/pubmed" id="34330765" target="_blank">34330765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37643054">
<a name="37643054"></a>Sakai D, Hirami Y, Sugita S, et al. A case of rapidly progressive retinopathy associated with pembrolizumab immunotherapy for metastatic urothelial carcinoma. <i>Retin Cases Brief Rep</i>. 2023;17(5):630-634. doi:10.1097/ICB.0000000000001257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37643054/pubmed" id="37643054" target="_blank">37643054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28438440">
<a name="28438440"></a>Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. <i>Eur J Cancer</i>. 2017;81:237-239. doi:10.1016/j.ejca.2017.03.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28438440/pubmed" id="28438440" target="_blank">28438440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35139274">
<a name="35139274"></a>Schmid P, Cortes J, Dent R, et al; KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer.<i> N Engl J</i>
<i>Med</i>. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/35139274/pubmed" id="35139274" target="_blank">35139274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32101663">
<a name="32101663"></a>Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. <i>N Engl J Med</i>. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32101663/pubmed" id="32101663" target="_blank">32101663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368439">
<a name="28368439"></a>Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. <i>Ann Oncol</i>. 2017;28(6):1403. doi:10.1093/annonc/mdx113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28368439/pubmed" id="28368439" target="_blank">28368439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27113507">
<a name="27113507"></a>Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. <i>Am J Kidney Dis</i>. 2016;68(2):287-291. doi:10.1053/j.ajkd.2016.02.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27113507/pubmed" id="27113507" target="_blank">27113507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28426103">
<a name="28426103"></a>Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. <i>Ann Oncol</i>. 2017;28(2):377-385. doi:10.1093/annonc/mdw558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28426103/pubmed" id="28426103" target="_blank">28426103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31008169">
<a name="31008169"></a>Sun CW, Grossman SK, Aphale A, Hsu S. Pembrolizumab-induced bullous pemphigoid. <i>JAAD Case Rep</i>. 2019;5(4):362-364. doi:10.1016/j.jdcr.2019.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31008169/pubmed" id="31008169" target="_blank">31008169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34454674">
<a name="34454674"></a>Sun JM, Shen L, Shah MA, et al; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i>. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/34454674/pubmed" id="34454674" target="_blank">34454674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29603856">
<a name="29603856"></a>Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. <i>Liver Int</i>. 2018;38(6):976-987. doi:10.1111/liv.13746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29603856/pubmed" id="29603856" target="_blank">29603856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33903584">
<a name="33903584"></a>Takatsuki K, Yanagihara T, Egashira A, et al. A rare case of pembrolizumab-induced dermatomyositis in a patient with cancer of unknown primary origin. <i>Am J Case Rep</i>. 2021;22:e930286. doi:10.12659/AJCR.930286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33903584/pubmed" id="33903584" target="_blank">33903584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36047125">
<a name="36047125"></a>Takigawa Y, Watanabe H, Omote Y, et al. Lambert-Eaton myasthenic syndrome recurrence induced by pembrolizumab in a patient with non-small-cell lung cancer. <i>Intern Med</i>. 2023;62(7):1055-1058. doi:10.2169/internalmedicine.0072-22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/36047125/pubmed" id="36047125" target="_blank">36047125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29730378">
<a name="29730378"></a>Tamura T, Akimoto E, Matsumoto C, et al. Vogt-Koyanagi-Harada Syndrome induced by pembrolizumab in a patient with non-small cell Lung Cancer. <i>J Thorac Oncol</i>. 2018;13(10):1606-1607. doi:10.1016/j.jtho.2018.04.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29730378/pubmed" id="29730378" target="_blank">29730378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30347480">
<a name="30347480"></a>Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. <i>Eur J Haematol</i>. 2019;102(2):157-162. doi:10.1111/ejh.13187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30347480/pubmed" id="30347480" target="_blank">30347480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30997872">
<a name="30997872"></a>Telfah M, Whittaker TJ, C Doolittle G. Vision loss with pembrolizumab treatment: A report of two cases. <i>J Oncol Pharm Pract</i>. 2019;25(6):1540-1546. doi:10.1177/1078155219841683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30997872/pubmed" id="30997872" target="_blank">30997872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33999581">
<a name="33999581"></a>Tsibris H, Lian C, Ho A. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma. <i>Dermatol Online J</i>. 2021;27(4):13030/qt4hs6n388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/33999581/pubmed" id="33999581" target="_blank">33999581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865922">
<a name="30865922"></a>Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. <i>J Natl Compr Canc Netw</i>. 2019;17(3):255-289. doi:10.6004/jnccn.2019.0013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/30865922/pubmed" id="30865922" target="_blank">30865922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31309615">
<a name="31309615"></a>Tsung I, Dolan R, Lao CD, Fecher L, Riggenbach K, Yeboah-Korang A, Fontana RJ. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. <i>Aliment Pharmacol Ther</i>. 2019;50(7):800-808. doi:10.1111/apt.15413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/31309615/pubmed" id="31309615" target="_blank">31309615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32691143">
<a name="32691143"></a>Uner M, Alhasson B, Obhrai J, Bagnasco SM. ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab. <i>Virchows Arch</i>. 2021;478(4):801-804. doi:10.1007/s00428-020-02882-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32691143/pubmed" id="32691143" target="_blank">32691143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26629425">
<a name="26629425"></a>Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. <i>Transl Lung Cancer Res</i>. 2015;4(5):560-575. doi:10.3978/j.issn.2218-6751.2015.06.06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/26629425/pubmed" id="26629425" target="_blank">26629425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32552471">
<a name="32552471"></a>Vuky J, Balar AV, Castellano D, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. <i>J Clin Oncol</i>. 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/32552471/pubmed" id="32552471" target="_blank">32552471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37272513">
<a name="37272513"></a>Wakelee H, Liberman M, Kato T, et al; KEYNOTE-671 Investigators. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. <i>N Engl J Med</i>. 2023;389(6):491-503. doi:10.1056/NEJMoa2302983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37272513/pubmed" id="37272513" target="_blank">37272513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37594534">
<a name="37594534"></a>Wang T, Guo W, Ren X, Lang F, Ma Y, Qiu C, Jiang J. Progress of immunotherapies in gestational trophoblastic neoplasms. <i>J Cancer Res Clin Oncol</i>. 2023;149(16):15275-15285. doi:10.1007/s00432-023-05010-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37594534/pubmed" id="37594534" target="_blank">37594534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22614989">
<a name="22614989"></a>Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. <i>J Clin Oncol</i>. 2012;30(21):2691-2697. doi:10.1200/JCO.2012.41.6750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/22614989/pubmed" id="22614989" target="_blank">22614989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28283736">
<a name="28283736"></a>Yamazaki N, Takenouchi T, Fujimoto M, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). <i>Cancer Chemother Pharmacol</i>. 2017;79(4):651-660. doi:10.1007/s00280-016-3237-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/28283736/pubmed" id="28283736" target="_blank">28283736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29875066">
<a name="29875066"></a>Zhu AX, Finn RS, Edeline J, et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [published correction appears in <i>Lancet Oncol</i>. 2018;19(9):e440]. <i>Lancet Oncol</i>. 2018;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/29875066/pubmed" id="29875066" target="_blank">29875066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27084345">
<a name="27084345"></a>Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>Eur J Cancer</i>. 2016;60:210-225. doi:10.1016/j.ejca.2016.02.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/27084345/pubmed" id="27084345" target="_blank">27084345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37130017">
<a name="37130017"></a>Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. <i>Blood</i>. 2023;142(2):141-145. doi:10.1182/blood.2022019340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pembrolizumab-drug-information/abstract-text/37130017/pubmed" id="37130017" target="_blank">37130017</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 96957 Version 321.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
